

Bonus CD-ROM
Available!
See Back Cover
for More Details



Remington

The Science and Practice of Pharmacy

21st EDITION



LIPPINCOTT WILLIAMS & WILKINS

Azurity Ex. 1004

IPR Petition – USP 12,128,039



21 ST EDITION

Remington

The Science and Practice of Pharmacy



21 ST EDITION

Remington

The Science and Practice of Pharmacy



LIPPINCOTT WILLIAMS & WILKINS

A Wolters Kluwer Company

Philadelphia • Baltimore • New York • London
Buenos Aires • Hong Kong • Sydney • Tokyo

Editor: David B. Troy
Managing Editor: Matthew J. Hauber
Marketing Manager: Marisa A. O'Brien

Lippincott Williams & Wilkins

351 West Camden Street
Baltimore, Maryland 21201-2436 USA

530 Walnut Street
Philadelphia, PA 19106

All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form or by any means, including photocopying, or utilized by any information storage and retrieval system without written permission from the copyright owner.

The publisher is not responsible (as a matter of product liability, negligence or otherwise) for any injury resulting from any material contained herein. This publication contains information relating to general principles of medical care which should not be construed as specific instructions for individual patients. Manufacturer's product information and package inserts should be reviewed for current information, including contraindications, dosages and precautions.

Printed in the United States of America

Entered according to Act of Congress, in the year 1885 by Joseph P Remington, in the Office of the Librarian of Congress, at Washington DC

Copyright 1889, 1894, 1905, 1907, 1917, by Joseph P Remington

Copyright 1926, 1936, by the Joseph P Remington Estate

Copyright 1948, 1951, by the Philadelphia College of Pharmacy and Science

Copyright 1956, 1960, 1965, 1970, 1975, 1980, 1985, 1990, 1995, by the Philadelphia College of Pharmacy and Science

Copyright 2000, 2006, by the University of the Sciences in Philadelphia

All Rights Reserved
Library of Congress Catalog Card Information is available

ISBN 10: 0-7817-4673-6
ISBN 13: 978-0-7817-4673-1

The publishers have made every effort to trace the copyright holders for borrowed material. If they have inadvertently overlooked any, they will be pleased to make the necessary arrangements at the first opportunity.

The use of structural formulas from USAN and the USP Dictionary of Drug Names is by permission of The USP Convention. The Convention is not responsible for any inaccuracy contained herein.

Notice—This text is not intended to represent, nor shall it be interpreted to be, the equivalent of or a substitute for the official United States Pharmacopeia (USP) and/or the National Formulary (NF). In the event of any difference or discrepancy between the current official USP or NF standards of strength, quality, purity, packaging and labeling for drugs and representations of them herein, the context and effect of the official compendia shall prevail.

To purchase additional copies of this book call our customer service department at **(800) 638-3030** or fax orders to **(301) 824-7390**. International customers should call **(301) 714-2324**.

Remington: The Science and Practice of Pharmacy . . . *A treatise on the theory and practice of the pharmaceutical sciences, with essential information about pharmaceutical and medicinal agents; also, a guide to the professional responsibilities of the pharmacist as the drug information specialist of the health team . . . A textbook and reference work for pharmacists, physicians, and other practitioners of the pharmaceutical and medical sciences.*

EDITORIAL BOARD

Paul Beringer

Pardeep K. Gupta

Ara DerMarderosian

John E. Hoover

Linda Felton

Nicholas G. Popovich

Steven Gelone

William J. Reilly, Jr

Alfonso R. Gennaro

Randy Hendrickson, Chair

AUTHORS

The 133 chapters of this edition of *Remington* were written by the editors, by members of the Editorial Board, and by the authors listed on pages xi to xv.

Director

Philip P Gerbino 1995-2005

Twenty-first Edition—2005

Published in the 185th year of the
PHILADELPHIA COLLEGE OF PHARMACY AND SCIENCE

Remington Historical/Biographical Data

The following is a record of the editors and the dates of publication of successive editions of this book, prior to the 13th Edition known as Remington's Practice of Pharmacy and subsequently as Remington's Pharmaceutical Sciences through the 20th edition.

First Edition, 1886

Second Edition, 1889

Third Edition, 1897

Fourth Edition, 1905

Joseph P. Remington

Fifth Edition, 1907

Sixth Edition, 1917

Joseph P. Remington

Assisted by
E. Fullerton Cook

Seventh Edition, 1926

Editors

E. Fullerton Cook
Charles H. LaWall

Eighth Edition, 1936

Editors

E. Fullerton Cook
Charles H. LaWall

Associated Editors
Ivor Griffith
Adley B. Nichols
Arthur Osol

Ninth Edition, 1948

Tenth Edition, 1951

Editors

E. Fullerton Cook
Eric W. Martin

Eleventh Edition, 1956

Editors

Eric W. Martin
E. Fullerton Cook

Associated Editors
E. Emerson Leuallen
Arthur Osol
Linwood F. Tice
Clarence T. Van Meter

Twelfth Edition, 1961

Editors

Eric W. Martin
E. Fullerton Cook
E. Emerson Leuallen
Arthur Osol
Linwood F. Tice
Clarence T. Van Meter

Assistant to the Editors
John E. Hoover

Thirteenth Edition, 1965

Editor-in-Chief

Eric W. Martin

Editors

Grafton D. Chase
Herald R. Cox
Richard A. Deno
Alfonso R. Gennaro
Stewart C. Harvey

Managing Editor

John E. Hoover

Robert E. King
E. Emerson Leuallen
Author Osol
Ewart A. Swinyard
Clarence T. Van Meter

Fourteenth Edition, 1970

Chairman, Editorial Board

Arthur Osol

Editors

Grafton D. Chase
Richard A. Deno
Alfonso R. Gennaro
Melvin R. Gibson
Stewart C. Harvey

Managing Editor

John E. Hoover

Robert E. King
Alfred N. Martin
Ewart A. Swinyard
Clarence T. Van Meter

Fifteenth Edition, 1975

Chairman, Editorial Board

Arthur Osol

Editors

John T. Anderson
Cecil L. Bendush
Grafton D. Chase
Alfonso R. Gennaro
Melvin R. Gibson

Managing Editor

John E. Hoover

C. Boyd Granberg
Stewart C. Harvey
Robert E. King
Alfred N. Martin
Ewart A. Swinyard

Sixteenth Edition, 1980

Chairman, Editorial Board

Arthur Osol

Editors

Grafton D. Chase
Alfonso R. Gennaro
Melvin R. Gibson

C. Boyd Granberg
Stewart C. Harvey
Robert E. King
Alfred N. Martin
Ewart A. Swinyard
Gilbert L. Zink

Seventeenth Edition, 1985

Chairman, Editorial Board

Alfonso R. Gennaro

Editors

Grafton D. Chase
Ara H. DerMarderosian
Stewart C. Harvey
Daniel A. Hussar
Thomas Medwick

Managing Editor

John E. Hoover

Edward G. Rippie
Joseph B. Schwartz
Ewart A. Swinyard
Gilbert L. Zink

Eighteenth Edition, 1990

Chairman, Editorial Board

Alfonso R. Gennaro

Editors

Grafton D. Chase
Ara H. DerMarderosian
Stewart C. Harvey
Daniel A. Hussar
Thomas Medwick

Managing Editor

John E. Hoover

Editorial Assistant
Bonnie Packer

Edward G. Rippie
Joseph B. Schwartz
Ewart A. Swinyard
Gilbert L. Zink

Nineteenth Edition, 1995

Chairman, Editorial Board
Alfonso R. Gennaro

Managing Editor
John E. Hoover
Editorial Assistant
Bonnie Packer

Editors

Grafton D. Chase
Ara H. DerMarderosian
Glen R. Hanson
Daniel A. Hussar
Thomas Medwick

Edward G. Rippie
Joseph B. Schwartz
H. Steve White
Gilbert L. Zink

Twentieth Edition, 2000

Chairman, Editorial Board
Alfonso R. Gennaro

Managing Editor
John E. Hoover
Editorial Assistant
Bonnie Packer

Editors

Ara DerMarderosian
Glen R. Hanson
Thomas Medwick
Nicholas G. Popovich

Roger L. Schnaare
Joseph B. Schwartz
H. Steve White

Oral Solid Dosage Forms

Edward M Rudnic, PhD
Joseph B Schwartz, PhD



Drug substances most frequently are administered orally by means of solid dosage forms such as tablets and capsules. Large-scale production methods used for their preparation, as described later in the chapter, require the presence of other materials in addition to the active ingredients. Additives also may be included in the formulations to facilitate handling, enhance the physical appearance, improve stability, and aid in the delivery of the drug to the bloodstream after administration. These supposedly inert ingredients, as well as the production methods employed, have been shown in many cases to influence the absorption or bioavailability of the drug substances.¹ Therefore, care must be taken in the selection and evaluation of additives and preparation methods to ensure that the drug-delivery goals and therapeutic efficacy of the active ingredient(s) will not be diminished.

In a number of cases it has been shown that the drug substance's solubility and other physicochemical characteristics

have influenced its physiological availability from a solid dosage form. These characteristics include its particle size, whether it is amorphous or crystalline, whether it is solvated or nonsolvated, and its crystalline, or polymorphic form. After clinically effective formulations are obtained, such variations among dosage units of a given batch, as well as batch-to-batch differences, should be reduced to a minimum through proper in-process controls and good manufacturing practices. The recognition of the importance of performance qualification, and validation for both equipment and processes has enhanced assurance in the reproducibility of solid dosage formulations greatly. It is in these areas that significant progress has been made with the realization that large-scale production of a satisfactory tablet or capsule depends not only on the availability of a clinically effective formulation but also on the raw materials, facilities, personnel, documentation, validated processes and equipment, packaging, and the controls used during and after preparation (Fig 45-1).

TABLETS

Tablets may be defined as solid pharmaceutical dosage forms containing drug substances with or without suitable diluents and have been traditionally prepared by either compression, or molding methods. Recently, punching of laminated sheets, electronic deposition methods, and three-dimensional printing methods have been used to make tablets. Tablets have been in widespread use since the latter part of the 19th century, and their popularity continues. The term *compressed tablet* is believed to have been used first by John Wyeth and Brother of Philadelphia. During this same period, molded tablets were introduced to be used as *hypodermic* tablets for the extemporaneous preparation of solutions for injection. Tablets remain popular as a dosage form because of the advantages afforded both to the manufacturer (eg, simplicity and economy of preparation, stability, and convenience in packaging, shipping, and dispensing) and the patient (eg, accuracy of dosage, compactness, portability, blandness of taste, and ease of administration).

Although the basic mechanical approach for most tablet manufacture has remained the same, tablet technology has undergone great improvement and experimentation. Efforts are being made continually to understand more clearly the physical characteristics of powder compaction and the factors affecting the availability of the drug substance from the dosage form after oral administration. Tableting equipment continues to improve in both production speed and the uniformity of tablets compressed. Recent advances in tablet technology have been reviewed.²⁻¹³

Although tablets frequently are discoid in shape, they also may be round, oval, oblong, cylindrical, or triangular. Other geometric shapes, such as diamonds and pentagons, and hexagons have also been used. They may differ greatly in size and weight depending on the amount of drug substance present and the intended method of administration. Most commercial tablets can be divided into two general classes by whether they are made by compression or molding. Compressed tablets usually are prepared by large-scale production methods, while molded tablets generally involve small-scale operations. The various tablet types and abbreviations used in referring to them are listed below.

COMPRESSED TABLETS (CT)—These tablets are formed by compression and in their simplest form, contain no special coating. They are made from powdered, crystalline, or granular materials, alone or in combination with binders, disintegrants, controlled-release polymers, lubricants, diluents, and in many cases colorants. The vast majority of tablets commercialized today are compressed tablets, either in an uncoated or coated state.

Sugar-Coated Tablets (SCT)—These are compressed tablets surrounded by a sugar coating. Such coatings may be colored and are beneficial in covering up drug substances possessing objectionable tastes or odors and in protecting materials sensitive to oxidation. These coatings were once quite common, and generally lost commercial appeal due to the high cost of process validation. Recently, they have made a comeback due to patient popularity and technical advances.

Film-Coated Tablets (FCT)—These are compressed tablets that are covered with a thin layer or film of a water-soluble material. A number of polymeric substances with film-forming properties may be used. Film coating imparts the same general characteristics as sugar coating,



Figure 45-1. Tablet press operators checking batch record in conformance with Current Good Manufacturing Practices (courtesy, Lilly).

with the added advantage of a greatly reduced time period required for the coating operation. Advances in material science and polymer chemistry has made these coatings the first-choice of formulators.

Enteric-Coated Tablets (ECT)—These are compressed tablets coated with substances that resist solution in gastric fluid but disintegrate in the intestine. Enteric coatings can be used for tablets containing drug substances that are inactivated or destroyed in the stomach, for those that irritate the mucosa, or as a means of delayed release of the medication.

Multiple Compressed Tablets (MCT)—These are compressed tablets made by more than one compression cycle. This process is best used when separation of active ingredients is needed for stability purposes, or if the mixing process is inadequate to guarantee uniform distribution of two or more active ingredients.

Layered Tablets—Such tablets are prepared by compressing additional tablet granulation on a previously compressed granulation. The operation may be repeated to produce multilayered tablets of two or three, or more layers. Special tablet presses are required to make layered tablets such as the Versa press (Stokes/Pennwalt).

Press-Coated Tablets—Such tablets, also referred to as dry-coated, are prepared by feeding previously compressed tablets into a special tableting machine and compressing another granulation layer around the preformed tablets. They have all the advantages of compressed tablets (ie, slotting, monogramming, speed of disintegration) while retaining the attributes of sugar-coated tablets in masking the taste of the drug substance in the core tablets. An example of a press-coated tablet press is the *Manesty Drycota*. Press-coated tablets also can be used to separate incompatible drug substances; in addition, they can provide a means of giving an enteric coating to the core tablets. Both types of multiple-compressed tablets have been used widely in the design of prolonged-action dosage forms.

Controlled-Release Tablets (CRT)—Compressed tablets can be formulated to release the drug slowly over a prolonged period of time. Hence, these dosage forms have been referred to as *prolonged-release* or *sustained-release* dosage forms as well. These tablets (as well as capsule versions) can be categorized into three types: (1) those that respond to some physiological condition to release the drug, such as enteric coatings; (2) those that release the drug in a relatively steady, controlled manner; and (3) those that combine combinations of mechanisms to release *pulses* of drug, such as repeat-action tablets. The performance of these systems is described in more detail in Chapter 47. Other names for these types of tablets can be: *Extended Release*, *Sustained Release*, *Prolonged Release*, *Delayed Release*, and in the case of pulsatile tablets, *Repeat Action*, *Pulsatile Release* or *Pulse Release*.

Tablets for Solution (CTS)—Compressed tablets to be used for preparing solutions or imparting given characteristics to solutions must be labeled to indicate that they are not to be swallowed. Examples of these tablets are Halazone Tablets for Solution and Potassium Permanganate Tablets for Solution.

Effervescent Tablets—In addition to the drug substance, these contain sodium bicarbonate and an organic acid such as tartaric or citric. In

the presence of water, these additives react, liberating carbon dioxide that acts as a disintegrator and produces effervescence. Except for small quantities of lubricants present, effervescent tablets are soluble.

Compressed Suppositories or Inserts—Occasionally, vaginal suppositories, such as Metronidazole tablets, are prepared by compression. Tablets for this use usually contain lactose as the diluent. In this case, as well as for any tablet intended for administration other than by swallowing, the label must indicate the manner in which it is to be used.

Buccal and Sublingual Tablets—These are small, flat, oval tablets. Tablets intended for buccal (the space between the lip and gum in the mouth) administration by inserting into the buccal pouch may dissolve or erode slowly; therefore, they are formulated and compressed with sufficient pressure to give a hard tablet. Progesterone tablets may be administered in this way. Some newer approaches have employed materials that act as bioadhesives to increase absorption of the drug.

Some other approaches use tablets that melt at body temperatures. The matrix of the tablet is solidified while the drug is in solution. After melting, the drug is automatically in solution and available for absorption, thus eliminating dissolution as a rate-limiting step in the absorption of poorly soluble compounds. Sublingual tablets, such as those containing nitroglycerin, isoproterenol hydrochloride, or erythrityl tetranitrate, are placed under the tongue. Sublingual tablets dissolve rapidly, and the drug substances are absorbed readily by this form of administration.

MOLDED TABLETS OR TABLET TRITURATES (TT)—Tablet triturates usually are made from moist material, using a triturate mold that gives them the shape of cut sections of a cylinder. Such tablets must be completely and rapidly soluble. The problem arising from compression of these tablets is the failure to find a lubricant that is completely water-soluble.

Dispensing Tablets (DT)—These tablets provide a convenient quantity of potent drug that can be incorporated readily into powders and liquids, thus circumventing the necessity to weigh small quantities. These tablets are supplied primarily as a convenience for extemporaneous compounding and should never be dispensed as a dosage form.

Hypodermic Tablets (HT)—Hypodermic tablets are soft, readily soluble tablets and originally were used for the preparation of solutions to be injected. Since stable parenteral solutions are now available for most drug substances, there is no justification for the use of hypodermic tablets for injection. Their use in this manner should be discouraged, since the resulting solutions are not sterile. Large quantities of these tablets continue to be made, but for oral administration. No hypodermic tablets ever have been recognized by the official compendia.

Compressed Tablets (CT)

For medicinal substances, with or without diluents, to be made into solid dosage forms with pressure, using available equipment, it is necessary that the material, either in crystalline or powdered form, possess a number of physical characteristics. These characteristics include the ability to flow freely, cohesiveness, and lubrication. The ingredients such as disintegrants designed to break the tablet up in gastrointestinal (GI) fluids and controlled-release polymers designed to slow drug release ideally should possess these characteristics or not interfere with the desirable performance traits of the other excipients. Since most materials have none or only some of these properties, methods of tablet formulation and preparation have been developed to impart these desirable characteristics to the material that is to be compressed into tablets.

The basic mechanical unit in all tablet-compression equipment includes a lower punch that fits into a die from the bottom and an upper punch, with a head of the same shape and dimensions, which enters the die cavity from the top after the tableting material fills the die cavity (Fig 45-2). The tablet is formed by pressure applied on the punches and subsequently is ejected from the die. The weight of the tablet is determined by the volume of the material that fills the die cavity. Therefore, the ability of the granulation to flow freely into the die is important in ensuring a uniform fill, as well as the continuous movement of the granulation from the source of supply or feed hopper. If the tablet granulation does not possess cohesive properties, the tablet after compression will crumble and fall apart on handling. As the punches must move freely within the




Figure 45-2. Basic mechanical unit for tablet compression: lower punch, die, and upper punch (courtesy, Vector/Colton).

die and the tablet must be ejected readily from the punch faces, the material must have a degree of lubrication to minimize friction and allow the removal of the compressed tablets.

There are three general methods typically used for commercial tablet preparation: the wet-granulation method, the dry-granulation method, and direct compression. The method of preparation and the added ingredients are selected to give the tablet formulation the desirable physical characteristics allowing the rapid compression of tablets. After compression, the tablets must have a number of additional attributes such as appearance, hardness, disintegration ability, appropriate dissolution characteristics, and uniformity, which also are influenced both by the method of preparation and by the added materials present in the formulation. In the preparation of compressed tablets, the formulator also must be cognizant of the effect that the ingredients and methods of preparation may have on the availability of the active ingredients and, hence, the therapeutic efficacy of the dosage form. In response to a request by physicians to change a dicumarol tablet so that it might be broken more easily, a Canadian company reformulated to make a large tablet with a score. Subsequent use of the tablet, containing the same amount of drug substance as the previous tablet, resulted in complaints that larger-than-usual doses were needed to produce the same therapeutic response. On the other hand, literature reports indicate that the reformulation of a commercial digoxin tablet resulted in a tablet that, although containing the same quantity of drug substance, gave the desired clinical response at half its original dose. Methods and principles that can be used to assess the effects of excipients and additives on drug absorption have been reviewed.^{2,14,15}

TABLET INGREDIENTS

In addition to the active or therapeutic ingredient, tablets contain a number of inert materials. The latter are known as additives or *excipients*. They may be classified according to the part they play in the finished tablet. The first group contains those that help to impart satisfactory processing and compression characteristics to the formulation. These include diluents, binders, glidants, and lubricants. The second group of added substances helps to give additional desirable physical characteristics to the finished tablet. Included in this group are disintegrants, surfactants, colors, and, in the case of chewable tablets, flavors, and sweetening agents, and in the case of controlled-release tablets, polymers or hydrophobic materials, such as waxes or other solubility-retarding materials. In some cases, anti-oxidants or other materials can be added to improve stability and shelf-life.

Although the term *inert* has been applied to these added materials, it has become apparent that there is an important relationship between the properties of the excipients and the dosage forms containing them. Preformulation studies demonstrate their influence on stability, bioavailability, and the processes by which the dosage forms are prepared. The need for ac-

quiring more information and use standards for excipients has been recognized in a joint venture of the Academy of Pharmaceutical Sciences and the Council of the Pharmaceutical Society of Great Britain. The result is called the *Handbook of Pharmaceutical Excipients*. This reference now is distributed widely throughout the world.¹⁶

Diluents

Frequently, the single dose of the active ingredient is small, and an inert substance is added to increase the bulk to make the tablet a practical size for compression. Compressed tablets of dexamethasone contain 0.75 mg steroid per tablet; hence, it is obvious that another material must be added to make tabletting possible. Diluents used for this purpose include dicalcium phosphate, calcium sulfate, lactose, cellulose, kaolin, mannitol, sodium chloride, dry starch, and powdered sugar. Certain diluents, such as mannitol, lactose, sorbitol, sucrose, and inositol, when present in sufficient quantity, can impart properties to some compressed tablets that permit disintegration in the mouth by chewing. Such tablets commonly are called *chewable tablets*. Upon chewing, properly prepared tablets will disintegrate smoothly at a satisfactory rate, have a pleasant taste and feel, and leave no unpleasant aftertaste in the mouth. Diluents used as excipients for direct compression formulas have been subjected to prior processing to give them flowability and compressibility. These are discussed under *Direct Compression*.

Most formulators of immediate-release tablets tend to use consistently only one or two diluents selected from the above group in their tablet formulations. Usually, these have been selected on the basis of experience and cost factors. However, in the formulation of new therapeutic agents, the compatibility of the diluents with the drug must be considered; eg, calcium salts used as diluents for the broad-spectrum antibiotic tetracycline have been shown to interfere with the drug's absorption from the GI tract. When drug substances have low water solubility, it is recommended that water-soluble diluents be used to avoid possible bioavailability problems. Highly adsorbent substances (eg, bentonite and kaolin) are to be avoided in making tablets of drugs used clinically in small dosage, such as the cardiac glycosides, alkaloids, and the synthetic estrogens. These drug substances may be adsorbed after administration. The combination of amine bases with lactose, or amine salts with lactose in the presence of an alkaline lubricant results in tablets that discolor on aging.

Microcrystalline cellulose (Avicel) usually is used as an excipient in direct-compression formulas. However, its presence in 5–15% concentrations in wet granulations has been shown to be beneficial in the granulation and drying processes in minimizing case-hardening of the tablets and in reducing tablet mottling.

Many ingredients are used for several different purposes, even within the same formulation (eg, cornstarch can be used in paste form as a binder). When added in drug or suspension form, it is a good disintegrant. Even though these two uses are to achieve opposite goals, some tablet formulas use cornstarch in both ways. In some controlled-release formulas, the polymer hydroxypropyl methylcellulose (HPMC) is used both as an aid to prolong the release from the tablet as well as a film-former in the tablet coating. Therefore, most excipients used in formulating tablets and capsules have many uses, and a thorough understanding of their properties and limitations is necessary to use them rationally.

Binders

Agents used to impart cohesive qualities to the powdered material are referred to as binders or granulators. They impart a cohesiveness to the tablet formulation that ensures the tablet remaining intact after compression, as well as improving the free-flowing qualities by the formulation of granules of desired hardness and size. Materials commonly used as binders include

starch, gelatin, and sugars such as sucrose, glucose, dextrose, molasses, and lactose. Natural and synthetic gums that have been used include acacia, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone, Veegum, and larch arabogalactan. Other agents that may be considered binders under certain circumstances are polyethylene glycol, ethylcellulose, waxes, water, and alcohol.

The quantity of binder used has considerable influence on the characteristics of the compressed tablets. The use of too much binder or too strong a binder will make a hard tablet that will not disintegrate easily and will cause excessive wear of punches and dies. Differences in binders used for CT Tolbutamide resulted in differences in hypoglycemic effects observed clinically. Materials that have no cohesive qualities of their own will require a stronger binder than those with these qualities. Alcohol and water are not binders in the true sense of the word, but because of their solvent action on some ingredients such as lactose, starch, and celluloses, they change the powdered material to granules, and the residual moisture retained enables the materials to adhere together when compressed.

Binders are used both as a solution and in a dry form, depending on the other ingredients in the formulation and the method of preparation. However, several *pregelatinized* starches available are intended to be added in the dry form so that water alone can be used as the granulating solution. The same amount of binder in solution will be more effective than if it were dispersed in a dry form and moistened with the solvent. By the latter procedure, the binding agent is not as effective in reaching and wetting each of the particles within the mass of powders. Each of the particles in a powder blend has a coating of adsorbed air on its surface, and it is this film that must be penetrated before the powders can be wetted by the binder solution. After wetting, a certain period of time is necessary to dissolve the binder completely and make it completely available for use. Since powders differ with respect to the ease with which they can be wetted and their rate of solubilization, it is preferable to incorporate the binding agent in solution. By this technique it often is possible to gain effective binding with a lower concentration of binder.

The direct-compression method for preparing tablets requires a material that is not only free-flowing but also sufficiently cohesive to act as a binder. This use has been described for a number of materials including microcrystalline cellulose, microcrystalline dextrose, amylose, and polyvinylpyrrolidone. It has been postulated that microcrystalline cellulose is a special form of cellulose fibril in which the individual crystallites are held together largely by hydrogen bonding. The disintegration of tablets containing the cellulose occurs by breaking the intercrystallite bonds by the disintegrating medium.

STARCH PASTE—Cornstarch is used widely as a binder. The concentration may vary from 10% to 20%. It usually is prepared as it is to be used, by dispersing cornstarch in sufficient cold purified water to make a 5–10% *w/w* suspension and warming in a water bath with continuous stirring until a translucent paste forms. It has been observed that during paste formation, not all of the starch is hydrolyzed. Starch paste then is not only useful as a binder, but also as a method to incorporate some disintegrant inside the granules.

GELATIN SOLUTION—Gelatin generally is used as a 10–20% solution; gelatin solutions should be prepared freshly as needed and used while warm or they will solidify. The gelatin is added to cold purified water and allowed to stand until it is hydrated. It then is warmed in a water bath to dissolve the gelatin, and the solution is made up to the final volume on a weight basis to give the concentration desired.

CELLULOSIC SOLUTIONS—Various cellulose derivatives have been used as binders in solution form. Hydroxypropyl methylcellulose (HPMC) has been used widely in this regard. Typical of a number of cellulose derivatives, HPMC is more soluble in cold water than hot. It also is more dispersible in hot water than cold. Hence, to obtain a good, smooth gel that is free from lumps or

fisheyes, it is necessary to add the HPMC in hot, almost boiling water and, under agitation, cool the mixture down as quickly as possible, as low as possible. Other water-soluble cellulose derivatives such as hydroxyethylcellulose (HEC) and hydroxypropylcellulose (HPC) have been used successfully in solution as binders.

Not all cellulose derivatives are soluble in water. Ethylcellulose can be used effectively when dissolved in alcohol or as a dry binder that then is wetted with alcohol. It is used as a binder for materials that are moisture-sensitive.

POLYVINYLPIRROLIDONE—PVP can be used as an aqueous or alcoholic solution, and this versatility has increased its popularity. Concentrations range from 2% and vary considerably.

It will be noted that binder solutions usually are made up to weight rather than volume. This is to enable the formulator to determine the weight of the solids that have been added to the tablet granulation in the binding solution. This becomes part of the total weight of the granulation and must be taken into consideration in determining the weight of the compressed tablet, which will contain the stated amount of the therapeutic agent.

As can be seen by the list of binders in this chapter, most modern binders used in solution are polymeric. Because of this, the flow or spreadability of these solutions becomes important when selecting the appropriate granulating equipment. The rheology of polymeric solutions is a fascinating subject in and of itself and should be considered for these materials.

Lubricants

Lubricants have a number of functions in tablet manufacture. They prevent adhesion of the tablet material to the surface of the dies and punches, reduce interparticle friction, facilitate the ejection of the tablets from the die cavity, and may improve the rate of flow of the tablet granulation. Commonly used lubricants include talc, magnesium stearate, calcium stearate, stearic acid, glyceryl behenate, hydrogenated vegetable oils, and polyethylene glycol (PEG). Most lubricants, with the exception of talc, are used in concentrations below 1%. When used alone, talc may require concentrations as high as 5%. Lubricants are in most cases hydrophobic materials. Poor selection or excessive amounts can result in *waterproofing* the tablets, resulting in poor tablet disintegration and/or delayed dissolution of the drug substance.

The addition of the proper lubricant is highly desirable if the material to be tableted tends to stick to the punches and dies. Immediately after compression, most tablets have the tendency to expand and will bind and stick to the side of the die. The choice of the proper lubricant will overcome this effectively.

The method of adding a lubricant to a granulation is important if the material is to perform its function satisfactorily. The lubricant should be divided finely by passing it through a 60- to 100-mesh nylon cloth onto the granulation. In production this is called *bolting* the lubricant. After adding the lubricant, the granulation is tumbled or mixed gently to distribute the lubricant without coating the particles too well or breaking them down to finer particles. Some research has concluded that the order of mixing of lubricants and other excipients can have a profound effect on the performance of the final dosage form. Thus, attention to the mixing process itself is just as important as the selection of lubricant materials.

These process variables can be seen in the prolonged blending of a lubricant in a granulation. Overblending materially can affect the hardness, disintegration time, and dissolution performance of the resultant tablets.

The quantity of lubricant varies, being as low as 0.1% and, in some cases, as high as 5%. Lubricants have been added to the granulating agents in the form of suspensions or emulsions. This technique serves to reduce the number of operational procedures and thus reduce the processing time.

In selecting a lubricant, proper attention must be given to its compatibility with the drug agent. Perhaps the most widely in-

vestigated drug is acetylsalicylic acid. Different talcs varied significantly the stability of aspirin. Talc with a high calcium content and a high loss on ignition was associated with increased aspirin decomposition. From a stability standpoint, the relative acceptability of tablet lubricants for combination with aspirin was found to decrease in the following order: hydrogenated vegetable oil, stearic acid, talc, and aluminum stearate.

The primary problem in the preparation of a water-soluble tablet is the selection of a satisfactory lubricant. Soluble lubricants reported to be effective include sodium benzoate, a mixture of sodium benzoate and sodium acetate, sodium chloride, leucine, and polyethylene glycol/Carbowax 4000. However, it has been suggested that formulations used to prepare water-soluble tablets may represent a number of compromises between compression efficiency and water solubility. While magnesium stearate is one of the most widely used lubricants, its hydrophobic properties can retard disintegration and dissolution. To overcome these waterproofing characteristics, sodium lauryl sulfate sometimes is included. One compound found to have the lubricating properties of magnesium stearate without its disadvantages is magnesium lauryl sulfate. Its safety for use in pharmaceuticals has not been established.

Glidants

A glidant is a substance that improves the flow characteristics of a powder mixture. These materials always are added in the dry state just prior to compression (ie, during the lubrication step). Colloidal silicon dioxide Cab-o-sil (*Cabot*) is the most commonly used glidant and generally is used in low concentrations of 1% or less. Talc (asbestos-free) also is used and may serve the dual purpose of lubricant/glidant.

It is especially important to optimize the order of addition and the mixing process for these materials, to maximize their effect and to make sure that their influence on the lubricant(s) is minimized.

Disintegrants

A disintegrant is a substance or a mixture of substances added to a tablet to facilitate its breakup or disintegration after administration. The active ingredient must be released from the tablet matrix as efficiently as possible to allow rapid dissolution. Materials serving as disintegrants have been classified chemically as starches, clays, celluloses, alginates, gums, and cross-linked polymers.

The oldest and still the most popular disintegrants are corn and potato starch that have been well dried and powdered. Starch has a great affinity for water and swells when moistened, thus facilitating the rupture of the tablet matrix. However, others have suggested that its disintegrating action in tablets is due to capillary action rather than swelling; the spherical shape of the starch grains increases the porosity of the tablet, thus promoting capillary action. Starch, 5%, is suggested, but if more rapid disintegration is desired, this amount may be increased to 10% or 15%. Although it might be expected that disintegration time would decrease as the percentage of starch in the tablet increased, this does not appear to be the case for tolbutamide tablets. In this instance, there appears to be a critical starch concentration for different granulations of the chemical. When their disintegration effect is desired, starches are added to the powder blends in the dry state.

A group of materials known as *super disintegrants* have gained in popularity as disintegrating agents. The name comes from the low levels (2–4%) at which they are completely effective. Croscarmellose, crospovidone, and sodium starch glycolate represent examples of a cross-linked cellulose, a cross-linked polymer, and a cross-linked starch, respectively.

The development of these disintegrants fostered new theories about the various mechanisms by which disintegrants

work. Sodium starch glycolate swells 7- to 12-fold in less than 30 sec. Croscarmellose swells 4- to 8-fold in less than 10 sec. The starch swells equally in all three dimensions, while the cellulose swells only in two dimensions, leaving fiber length essentially the same. Since croscarmellose is the more efficient disintegrating agent, it is postulated that the rate, force, and extent of swelling play an important role in those disintegrants that work by swelling. Cross-linked PVP swells little but returns to its original boundaries quickly after compression. Wicking, or capillary action, also is postulated to be a major factor in the ability of cross-linked PVP to function.^{17–19}

In addition to the starches, a large variety of materials have been used and are reported to be effective as disintegrants. This group includes Veegum HV, methylcellulose, agar, bentonite, cellulose and wood products, natural sponge, cation-exchange resins, alginic acid, guar gum, citrus pulp, and carboxymethylcellulose.²⁰ Sodium lauryl sulfate in combination with starch also has been demonstrated to be an effective disintegrant. In some cases the apparent effectiveness of surfactants in improving tablet disintegration is postulated as due to an increase in the rate of wetting.

The disintegrating agent usually is mixed with the active ingredients and diluents prior to granulation. In some cases it may be advantageous to divide the starch into two portions: one part is added to the powdered formula prior to granulation, and the remainder is mixed with the lubricant and added prior to compression. Incorporated in this manner, the starch serves a double purpose; the portion added to the lubricant rapidly breaks down the tablet to granules, and the starch mixed with the active ingredients disintegrates the granules into smaller particles. Veegum has been shown to be more effective as a disintegrator in sulfathiazole tablets when most of the quantity is added after granulation and only a small amount before granulation. Likewise, the montmorillonite clays were found to be good tablet disintegrants when added to prepared granulations as powder. They are much less effective as disintegrants when incorporated within the granules.

Factors other than the presence of disintegrants can affect the disintegration time of compressed tablets significantly. The binder, tablet hardness, and the lubricant have been shown to influence the disintegration time. Thus, when the formulator is faced with a problem concerning the disintegration of a compressed tablet, the answer may not lie in the selection and quantity of the disintegrating agent alone.

The evolution of carbon dioxide is also an effective way to cause the disintegration of compressed tablets. Tablets containing a mixture of sodium bicarbonate and an acidulant such as tartaric or citric acid will effervesce when added to water. Sufficient acid is added to produce a neutral or slightly acidic reaction when disintegration in water is rapid and complete. One drawback to the use of the effervescent type of disintegrator is that such tablets must be kept in a dry atmosphere at all times during manufacture, storage, and packaging. Soluble, effervescent tablets provide a popular form for dispensing aspirin and noncaloric sweetening agents.

Coloring Agents

Colors in compressed tablets serve functions other than making the dosage form more esthetic in appearance. Color helps the manufacturer to control the product during its preparation, as well as serving as a means of identification to the user. The wide diversity in the use of colors in solid dosage forms makes it possible to use color as an important category in the identification code developed by the AMA to establish the identity of an unknown compressed tablet in situations arising from poisoning.

All colorants used in pharmaceuticals must be approved and certified by the FDA. For several decades colorants have been subjected to rigid toxicity standards, and as a result, a number of colorants have been removed from an approved list of Food, Drug and Cosmetic Act (FD&C) colors, or *delisted*. Several have

Table 45-1. Colors Approved for Use in the US in Oral Dosage Forms^{a,b}

COLOR	OTHER NAMES	COLOR INDEX (CI 1971)	USE RESTRICTION (US)
FD&C Red 40	Allura red	16035	FDA certification on each lot of dye
D&C Red 33	Acid fuchsin D	17200	ADI 0–0.76 mg
	Naphtalene red B		
D&C Red 36			ADI 0–1.0 mg
Canthaxanthin	Food orange 8	40850	None
D&C Red 22	Eosin Y	45380	FDA certification on each lot of dye
D&C Red 28	Phloxine B	45410	FDA certification on each lot of dye
D&C Red 3	Erythrosine	45430	FDA certification on each lot of dye
Cochineal extract	Natural red 4	75470	None
	Carmine		
Iron oxide—red	—	77491	ADI 0–5 mg elemental iron
FD&C Yellow 6	Sunset yellow FCF	15985	None
	Yellow orange 5		
FD&C Yellow 5	Tartrazine	19140	Label declaration and FDA certification on each lot of dye
D&C Yellow 10	Quinoline yellow WS	47005	FDA certification on each lot of dye
Beta-carotene	—	40800	
Iron oxide—yellow	—	77492	ADI 0–5 mg elemental iron
FD&C Blue 1	Brilliant blue FCF	42090	FDA certification on each lot of dye
FD&C Blue 2	Indigotine	73015	None
	Indigo carmine		
FD&C Green 3	Fast green FCF	42035	FDA certification on each lot of dye
Iron oxide—black	—	77499	ADI 0–5 mg elemental iron
Caramel	Burnt sugar	—	None
Titanium dioxide	—	77891	None

^a Abbreviations: ADI, acceptable daily intake (per kg body weight); CI, color index numbers of 1971 (US); D&C, Drug and Cosmetic Dyes (US); FD&C, Food, Drug and Cosmetic Dyes (US); FDA, Food and Drug Administration (US).

^b As of February, 1988 and subject to revision.

been listed as well. The colorants currently approved in the US are listed in Table 45-1. Each country has its own list of approved colorants, and formulators must consider this in designing products for the international market.²¹

Any of the approved, certified, water-soluble FD&C dyes, mixtures of the same, or their corresponding lakes may be used to color tablets. A color lake is the combination by adsorption of a water-soluble dye to a hydrous oxide of a heavy metal resulting in an insoluble form of the dye. In some instances multiple dyes are used to give a purposefully heterogeneous coloring in the form of speckling to compressed tablets. The dyes available do not meet all the criteria required for the ideal pharmaceutical colorants. The photosensitivity of several of the commonly used colorants and their lakes has been investigated, as well as the protection afforded by a number of glasses used in packaging tablets.

Another approach for improving the photostability of dyes has been in the use of ultraviolet-absorbing chemicals in the tablet formulations with the dyes. The Di-Pac line (*Amstar*) is a series of commercially available colored, direct-compression sugars.

The most common method of adding color to a tablet formulation is to dissolve the dye in the binding solution prior to the granulating process. Another approach is to adsorb the dye on starch or calcium sulfate from its aqueous solution; the resultant powder is dried and blended with the other ingredients. If the insoluble lakes are used, they may be blended with the other dry ingredients. Frequently during drying, colors in wet granulations migrate, resulting in an uneven distribution of the color in the granulation. After compression, the tablets will have a mottled appearance due to the uneven distribution of the color. Migration of colors may be reduced by drying the granulation slowly at low temperatures and stirring the granulation while it is drying. The affinity of several water-soluble, anionic, certified dyes for natural starches has been demonstrated; in these cases this affinity should aid in preventing color migration.

Other additives have been shown to act as dye-migration inhibitors. Tragacanth (1%), acacia (3%), attapulgit (5%), and talc (7%) were effective in inhibiting the migration of FD&C Blue No 1 in lactose. In using dye lakes, the problem of color mi-

gration is avoided since the lakes are insoluble. Prevention of mottling can be helped also by the use of lubricants and other additives that have been colored similarly to the granulation prior to their use. The problem of mottling becomes more pronounced as the concentration of colorants increases. Color mottling is an undesirable characteristic common to many commercial tablets.

Flavoring Agents

In addition to the sweetness that may be afforded by the diluent of the chewable tablet, eg, mannitol or lactose, artificial sweetening agents may be included. Formerly, the cyclamates, either alone or in combination with saccharin, were used widely. With the banning of the cyclamates and the indefinite status of saccharin, new natural sweeteners are being sought. Aspartame (*Pfizer*), has found applications in pharmaceutical formulations. Sweeteners other than the sugars have the advantage of reducing the bulk volume, considering the quantity of sucrose required to produce the same degree of sweetness. Being present in small quantities, they do not affect markedly the physical characteristics of the tablet granulation.

POWDER COMPACTION

Compressed tablets became a commercially viable and efficient dosage form with the invention of tablet machines. In 1843 William Brockendon, a British inventor, author, artist, and watchmaker, received British Patent #9977 for *Shaping Pills, Lozenges, and Black Lead by Pressure in Dies*.²² In over 150 years of tablet manufacture, the basic process has not changed. Surprisingly, improvements have been made only with regards to speed of manufacture and quality control.

The process of compaction has several identifiable phases. As can be seen in Figure 45-3, when powders undergo compression (a reduction in volume), the first process to occur is a consolidation of the powders. During this consolidation phase, the powder particles adopt a more efficient packing order. The second phase of the compaction process is elastic, or reversible de-




Figure 45-3. The stages of powder compaction.

formation. If the force were to be removed during this phase, the powder would recover completely to the efficiently packed state. For most pharmaceutical powders, this phase is very short in duration and very difficult to identify on most instrumented tablet presses. The third phase of compaction is plastic, or irreversible, deformation of the powder bed. It is this phase of the compaction process that is the most critical in tablet formation. If too much force is applied to the powder, brittle fracture occurs. If the force was applied too quickly, fracture and de-bonding during stress relaxation can occur.

In 1950, Stewart reported on the importance of plastic flow and suggested that if a material has significant plastic flow under compression, it will be more likely to form a compact.²³ David and Augsburg evaluated stress-relaxation data, using the Maxwell model of viscoelastic behavior in an attempt to quantify the rate of plastic deformation of some direct compression excipients.²⁴ Jones has used the term *contact time* to describe the total time for which a moving punch applies a detectable force to the die contents during the compression and decompression event, excluding ejection.²⁵

Rees and Rue evaluated three parameters: stress relation during compaction, effect of contact time on tablet density, and rate of application of diametrical compression on tablet deformation.²⁶

Jones²⁵ outlined numerous techniques to evaluate the compactability of powders. Because of the completeness of his review, these parameters are discussed below.

Tablet Strength—Compression Pressure Profile

Most formulators use tablet *hardness*, or tensile strength, as a measure of the cohesiveness of a tablet. With even the simplest of instrumented tablet presses, it is possible to plot tensile strength versus the force applied to the tablet. Figure 45-4 illustrates such a plot. These plots can be useful in identifying forces that can cause fracture and can lead to a quick, tangible assessment of the compatibility of the formulation. However, there are many limitations to this method, as these plots cannot predict *lamination* or *capping*. In addition, the cohesiveness of a tablet can change upon storage, in either a positive or negative direction.

Tablet Friability

This test is discussed later in the chapter, and there have been many suggestions about how they should be performed. Many formulators believe this is an important indicator of cohesiveness but is of limited value in predicting failure in the field.

Changes in Bed Density during Compression

As applied stress (force) increases, elastic and plastic deformation of the particles occurs, which results in plastic flow and a reduction in inter- and intraparticle void spaces. This lowers the overall compact density.

For highly cohesive systems, the reduction in void space may yield a compact of sufficient strength for insertion into a capsules shell. However, the inherent cohesiveness for most drugs and excipients is not suitable alone for tablet manufacture.

The Heckel equation is given below; K can be considered equal to the reciprocal of the mean yield pressure, and A is a function of the original compact volume and is related to the densification and particle rearrangement prior to bonding.

$$\text{Log } [1/(1 - D)] = KP + A$$

where D is the relative density at pressure P , and K and A are constants.

Hersey and Rees²⁸ have classified Heckel plots into two categories. Figure 45-5 shows both types of Heckel plots. Type 2 differs from Type 1 in that above a certain pressure a single linear relationship occurs irrespective of the initial bed density.




Figure 45-4. Tensile strength of compacts prepared from different crystal forms. A: Barbitone (104–152 μm)—○, Form I; □, Form II; △, Form III. B: Sulfathiazole (104–152 μm)—○, Form I; △, Form II. C: Aspirin (250–353 μm)—△, Form I; □, Form IV. (From Summers MP, Enever RP, Carless JE. *J Pharm Sci* 1977; 66:1172.)




Figure 45-5. Heckel plots. A: Type I. B: Type II. (From Jones TM. *Acta Pharm Tech* 1978.)

This is independent of particle size and is probable due to fragmentation of particles and their subsequent compaction by plastic deformation. For Type 1 materials, no such fracture occurs, but adjacent particles simply deform plastically.

The pressure at which the plots transition to a linear portion is approximately equal to the minimum pressure required to form a coherent compact.

Changes in Surface Area During Compression

Bulk powders change their state of packing during compaction, and individual particles fracture and/or plastically deform. During this process, the surface area of the powders and the compact in whole, changes. Conventional nitrogen absorption techniques can estimate these changes. Although this can be tedious, these measurements can give a means of examining lamination tendency.

Stress Relaxation

The experimental technique consists of holding the compression process at a point of maximum compression and observing the compression force over various periods of time. By increas-

ing the duration of this period (dwell time), plastic flow is maximized, and tablet strength increases.

Stress Transmissions during Compression

If the stresses in the upper punch, lower punch, and die wall are monitored, as in Figure 45-6, a general plot can be constructed showing the relationship between these forces. The elastic limit is reached at point A. At point B, the applied force is released, and the transmitted force on the wall of the die falls rapidly. The upper punch ceases to contact the powder/compact at point C, where the transmitted force falls rapidly to a residual force, point D. The force needed to eject the tablet from the die must be greater than the residual force holding it to the sides of the die. Therefore, residual forces tend to be proportional to ejection forces. In addition, these plots can give a good assessment of the elastic component of the compaction process of a powder.

Work and Compaction

Force-displacement ($F-D$) curves are useful in determining the work involved in forming a compact. Curves, such as shown in Figure 45-7,²⁹ represent the work of the compression process, but all compacts expand somewhat during decompression, and this force is transferred back to the punch. Therefore, by performing a second compression of the compact, the second result can be subtracted from the first for a *corrected F-D curve*. The corrected curve represents the work associated with plastic deformation during powder compaction, as well as a determination of the work of friction of the die wall and the work of elastic deformation.

GRANULATION METHODS

Wet Granulation

The most widely used and most general method of tablet preparation is the wet-granulation method. Its popularity is due to the greater probability that the granulation will meet all the physical requirements for the compression of good tablets. Its chief disadvantages are the number of separate steps involved, as well as the time and labor necessary to carry out the procedure, especially on a large scale. The steps in the wet method are weighing, mixing, granulation, screening the damp mass, drying, dry screening, lubrication, and compression. The equipment involved depends on the quantity or size of the batch. The active ingredient, diluent, and disintegrant are mixed or blended well. For small batches the ingredients may be mixed in stainless steel bowls or mortars. Small-scale blending also




Figure 45-6. Transmitted stresses during tablet compaction.




Figure 45-7. Typical forces. A: Displacement (F–D) curve; B: displacement (F–D), second compression. (From Jones TM. *Acta Pharm Tech* 1978.)

can be carried out on a large piece of paper by holding the opposite edges and tumbling the material back and forth. The powder blend may be sifted through a screen of suitable fineness to remove or break up lumps. This screening also affords additional mixing. The screen selected always should be of the same type of wire or cloth that will not affect the potency of the ingredients through interaction. For example, the stability of ascorbic acid is affected deleteriously by even small amounts of copper, thus care must be taken to avoid contact with copper or copper-containing alloys.

For larger quantities of powder, the Patterson-Kelley twin-shell blender and the double-cone blender offer a means of precision blending and mixing in short periods of time (Fig 45-8). Twin-shell blenders are available in many sizes from laboratory models to large production models. Planetary mixers (eg,




Figure 45-8. Twin-shell blender for solids or liquid-solids blending (courtesy, Patterson-Kelley).

the Glen mixer and the Hobart mixer) have served this function in the pharmaceutical industry for many years (Fig 45-9). On a large scale, ribbon blenders also are employed frequently and may be adapted for continuous-production procedures. Mass mixers of the sigma-blade type have been used widely in the pharmaceutical industry.

Highly popular are the high-speed, high-shear mixers such as the Diosna, Fielder, Lodge/Littleford, and Baker-Perkins. For these mixers a full range of sizes are available. The processing of granulations in these machines is generally faster than in conventional granulators. However, control over the process is critical, and scale-up issues may become extremely important.³⁰ Fluid-bed granulation (discussed below) also is gaining wide acceptance in the industry. For both of these types of processing, slight modifications to the following procedures are required.




Figure 45-9. The Glen powder mixer (courtesy, Am Machine).




Figure 45-10. Rotary granulator and sifter (courtesy, Vector/Colton).

Solutions of the binding agent are added to the mixed powders with stirring. The powder mass is wetted with the binding solution until the mass has the consistency of damp snow or brown sugar. If the granulation is over-wetted, the granules will be hard, requiring considerable pressure to form the tablets, and the resultant tablets may have a mottled appearance. If the powder mixture is not wetted sufficiently, the resulting granules will be too soft, breaking down during lubrication and causing difficulty during compression.

The wet granulation is forced through a 6- or 8-mesh screen. Small batches can be forced through by hand using a manual screen. For larger quantities, one of several comminuting mills suitable for wet screening can be used. These include the Stokes oscillator, Colton rotary granulator, Fitzpatrick comminuting mill, or Stokes tornado mill. See Figure 45-10. In comminuting mills the granulation is forced through the sieving device by rotating hammers, knives, or oscillating bars. Most high-speed mixers are equipped with a chopper blade that operates independently of the main mixing blades and can replace the wet milling step, ie, can obviate the need for a separate operation.

For tablet formulations in which continuous production is justified, extruders such as the Reitz extruder have been adapted for the wet-granulation process. The extruder consists of a screw mixer with a chamber where the powder is mixed with the binding agent, and the wet mass gradually is forced through a perforated screen, forming threads of the wet granulation. The granulation then is dried by conventional methods. A semiautomatic, continuous process using the Reitz extruder has been described for the preparation of the antacid tablet *Gelusil* (Warner-Lambert/Pfizer).

Moist material from the wet milling step traditionally was placed on large sheets of paper on shallow wire trays and placed in drying cabinets with a circulating air current and thermostatic heat control. See Figure 45-11. While tray drying was the most widely used method of drying tablet granulations in the past, fluid-bed drying is now considered the standard. In drying tablet granulation by fluidization, the material is suspended and agitated in a warm air stream while the granulation is maintained in motion. Drying tests comparing the fluidized bed

and a tray dryer for a number of tablet granulations indicated that the former was 15 times faster than the conventional method of tray drying. In addition to the decreased drying time, the fluidization method is claimed to have other advantages such as better control of drying temperatures, decreased handling costs, and the opportunity to blend lubricants and other materials into the dry granulation directly in the fluidized bed. See Figure 45-12.³¹

The application of microwave drying and infrared drying to tablet granulations has been reported as successful for most granulations tried. These methods readily lend themselves to continuous granulation operations. The study of drying methods for tablet granulations led to the development of the Rovac dryer system by Ciba/Novartis pharmacists and engineers. The dryer is similar in appearance to the cone blender except for the heating jacket and vacuum connections. By excluding oxygen and using the lower drying temperatures made possible by drying in a vacuum, opportunities for degradation of the ingredients during the drying cycle are minimized. A greater uniformity of residual moisture content is achieved because of the moving bed, controlled temperature, and controlled time period of the drying cycle. Particle-size distribution can be controlled by varying the speed of rotation and drying temperature as well as by comminuting the granulation to the desired granule size after drying.

In drying granulations it is desirable to maintain a residual amount of moisture in the granulation. This is necessary to maintain the various granulation ingredients, such as gums, in a hydrated state. Also, the residual moisture contributes to the reduction of the static electric charges on the particles. In the selection of any drying process, an effort is made to obtain a uniform moisture content. In addition to the importance of moisture content of the granulation in its handling during the manufacturing steps, the stability of the products containing moisture-sensitive active ingredients may be related to the moisture content of the products.

Previously it was indicated that water-soluble colorants can migrate toward the surface of the granulation during the drying process, resulting in mottled tablets after compression. This is also true for water-soluble drug substances, resulting in tablets unsatisfactory as to content uniformity. Migration can be reduced by drying the granulation slowly at low temperatures or using a granulation in which the major diluent is present as granules of large particle size. The presence of microcrystalline cellulose in wet granulations also reduces migration tendencies.

After drying, the granulation is reduced in particle size by passing it through a smaller-mesh screen. Following dry screening, the granule size tends to be more uniform. For dry granulations the screen size to be selected depends on the diameter of the punch. The following sizes are suggested:

- Tablets up to $\frac{1}{16}$ inch diameter, use 20-mesh
- Tablets $\frac{1}{16}$ to $\frac{1}{8}$ inch, use 16-mesh
- Tablets $\frac{1}{8}$ to $\frac{1}{4}$ inch, use 14-mesh
- Tablets $\frac{1}{4}$ inch and larger, use 12-mesh

For small amounts of granulation, hand screens may be used and the material passed through with the aid of a stainless steel spatula. With larger quantities, any of the comminuting mills




Figure 45-11. Cross-section of tray dryer.




Figure 45-12. Three versions of fluidized-bed granulation and drying. A: Top-spray method used in conventional fluid-bed granulation coaters; B: bottom-spray method used in Wurster air-suspension columns; C: tangential-spray method used in rotary fluid-bed coaters/granulators. (Courtesy, Aster Publ, adapted from Mehta AM. *Pharm Technol* 1988; 12:46.)

with screens corresponding to those just mentioned may be used. Note that the smaller the tablet, the finer the dry granulation to enable more uniform filling of the die cavity; large granules give an irregular fill to a comparatively small die cavity. With compressed tablets of sodium bicarbonate, lactose, and magnesium trisilicate, a relationship has been demonstrated between the particle size of the granulated material and the disintegration time and capping of the resultant tablets. For a sulfathiazole granulation, however, the particle-size distribution did not appear to influence hardness or disintegration.

After dry granulation, the lubricant is added as a fine powder. It usually is screened onto the granulation through 60- or 100-mesh nylon cloth to eliminate small lumps as well as to increase the covering power of the lubricant. As it is desirable for each granule to be covered with the lubricant, the lubricant is blended with the granulation very gently, preferably in a blender using a tumbling action. Gentle action is desired to maintain the uniform granule size resulting from the granulation step. It has been claimed that too much fine powder is not desirable because fine powder may not feed into the die evenly; consequently, variations in weight and density result. Fine powders, commonly designated as *fines*, also blow out around the upper punch and down past the lower punch, making it necessary to clean the machine frequently. Fines, however, at a level of 10–20%, traditionally are sought by the tablet formulator. The presence of some fines is necessary for the proper filling of the die cavity. Now, even higher concentrations of fines are used successfully in tablet manufacture. Most investigators agree that no general limits exist for the amount of fines that can be present in a granulation; it must be determined for each specific formula.

Many formulators once believed (and some still believe) that overblending resulted in an increased amount of fines and, hence, caused air entrapment in the formula. The capping and laminating of tablets associated with overblending lubricants was thought to be caused by these air pockets. Most scientists now recognize that a more plausible explanation has to do with the function of the lubricants themselves. Since the very nature of a lubricant tends to make surfaces less susceptible to adhesion, overblending prevents the intergranular bonding that takes place during compaction.

Fluid-Bed Granulation

A new method for granulating evolved from the fluid-bed drying technology described earlier. The concept was to spray a granulating solution onto the suspended particles, which then would be dried rapidly in the suspending air. The main benefit from this system is the rapid granulation and drying of a batch. The two main firms that developed this technology are *Glatt* and *Aeromatic* (now *NIRO*). The design of these systems is basically the same with both companies (see Fig 45-12). In this method, particles of an inert material or the active drug are suspended in a vertical column with a rising air stream; while the particles are suspended, the common granulating materials in solution are sprayed into the column. There is a gradual particle buildup under a controlled set of conditions resulting in a tablet granulation that is ready for compression after the addition of the lubricant. An obvious advantage exists, since granulating and drying can take place in a single piece of equipment. It should be noted, however, that many of the mixers discussed previously can be supplied with a steam jacket and vacuum and can provide the same advantage.

In these systems a granulating solution or solvent is sprayed into or onto the bed of suspended particles. The rate of addition of the binder, temperature in the bed of particles, temperature of the air, volume, and moisture of the air all play an important role in the quality and performance of the final product. Many scientists feel that this method is an extension of the wet-granulation method, as it incorporates many of its concepts. However anyone who has developed a formulation in a fluid-bed

system knows that the many operating parameters involved make it somewhat more complex.³¹ In addition to its use for the preparation of tablet granulations, this technique also has been proposed for the coating of solid particles as a means of improving the flow properties of small particles. Researchers have observed that, in general, fluid-bed granulation yields a less dense particle than conventional methods, and this can affect subsequent compression behavior. A large-scale fluid-bed granulation process has been described for Tylenol (*McNeil*). Methods for the preparation of compressed tablets have been reviewed in the literature.³²

The *Merck* facility at Elkton, VA was the first completely automated tablet production facility in the world. The entire tablet-manufacturing process based on a wet-granulation method was computer-controlled. By means of a computer, the system weighed the ingredients, blended, granulated, dried, and lubricated to prepare a uniform granulation of specified particle size and particle-size distribution. The computer directed the compression of the material into tablets with exacting specifications for thickness, weight, and hardness. After compression, the tablets were coated with a water-based film coating. The computer controlled and monitored all flow of material. The plant represented the first totally automated pharmaceutical manufacturing facility. However, due to shifting market trends and the burdens of process validation and changes to processes, totally automated processes are generally not used today. Instead, many production operations focus on computer-controlled and monitored unit operations, such as seen in various tableting machines and granulators today. See Figure 45-13.


Equipment suppliers work closely with individual pharmaceutical companies in designing specialized and unique systems.

Dry Granulation

When tablet ingredients are sensitive to moisture or are unable to withstand elevated temperatures during drying, and when the tablet ingredients have sufficient inherent binding or cohesive properties, slugging may be used to form granules. This method is referred to as dry granulation, precompression, or double-compression. It eliminates a number of steps but still includes weighing, mixing, slugging, dry screening, lubrication, and compression. The active ingredient, diluent (if required), and part of the lubricant are blended. One of the constituents, either the active ingredient or the diluent, must have cohesive properties. Powdered material contains a considerable amount of air; under pressure this air is expelled, and a fairly dense piece is formed. The more time allowed for this air to escape, the better the tablet or slug.

When slugging is used, large tablets are made as slugs because fine powders flow better into large cavities. Also, producing large slugs decreases production time; 7/8 to 1 in are the most practical sizes for slugs. Sometimes, to obtain the pressure that is desired the slug sizes are reduced to 3/4 in. The punches should be flat-faced. The compressed slugs are comminuted through the desirable mesh screen either by hand or, for larger quantities, through the Fitzpatrick or similar comminuting mill. The lubricant remaining is added to the granulation and blended gently, and the material is compressed into tablets. Aspirin is a good example of where slugging is satisfactory. Other materials such as aspirin combinations, acetaminophen, thiamine hydrochloride, ascorbic acid, magnesium hydroxide, and other antacid compounds may be treated similarly.

Results comparable to those accomplished by the slugging process also are obtained with compacting mills. In the com-



A

Figure 45-13. Fixed automated processes in the 1980s have given way to flexible micro-processor controlled unit operations. **a.** Computer control room for the first large-scale computer-controlled tablet manufacturing facility (courtesy, Merck).



Figure 45-13. (continued) **b.** Computer-controlled/monitored coating.

paction method the powder to be densified passes between high-pressure rollers that compress the powder and remove the air. The densified material is reduced to a uniform granule size and compressed into tablets after the addition of a lubricant. Excessive pressures that may be required to obtain cohesion of certain materials may result in a prolonged dissolution rate. Compaction mills available include the Chilsonator (*Fitzpatrick*), Roller Compactor (*Vector*), and the Compactor Mill (*Allis-Chalmers*).

Direct Compression

As its name implies, direct compression consists of compressing tablets directly from powdered material without modifying the

physical nature of the material itself. Formerly, direct compression as a method of tablet manufacture was reserved for a small group of crystalline chemicals having all the physical characteristics required for the formation of a good tablet. This group includes chemicals such as potassium salts (chlorate, chloride, bromide, iodide, nitrate, permanganate), ammonium chloride, and methenamine. These materials possess cohesive and flow properties that make direct compression possible.

Since the pharmaceutical industry constantly is making efforts to increase the efficiency of tableting operations and reduce costs by using the smallest amount of floor space and labor as possible for a given operation, increasing attention is being given to this method of tablet preparation. Approaches being used to make this method more universally applicable include the introduction of formulation additives capable of im-




Figure 45-13. (continued) c. Computer-controlled/monitored granulation.

parting the characteristics required for compression and the use of force-feeding devices to improve the flow of powder blends.

For tablets in which the drug itself constitutes a major portion of the total tablet weight, it is necessary that the drug possess those physical characteristics required for the formulation to be compressed directly. Direct compression for tablets containing 25% or less of drug substances frequently can be used by formulating with a suitable diluent that acts as a carrier or vehicle for the drug.³²⁻³⁴

Direct-compression vehicles or carriers must have good flow and compressible characteristics. These properties are imparted to them by a preprocessing step such as wet granulation, slugging, spray drying, spheronization, or crystallization. These vehicles include processed forms of most of the common diluents including dicalcium phosphate dihydrate, tricalcium

phosphate, calcium sulfate, anhydrous lactose, spray-dried lactose, pregelatinized starch, compressible sugar, mannitol, and microcrystalline cellulose. These commercially available direct-compression vehicles may contain small quantities of other ingredients (eg, starch) as processing aids. Dicalcium phosphate dihydrate (Di-Tab, *Stauffer*) in its unmilled form has good flow properties and compressibility. It is a white, crystalline agglomerate insoluble in water and alcohol. The chemical is odorless, tasteless, and nonhygroscopic. Since it has no inherent lubricating or disintegrating properties, other additives must be present to prepare a satisfactory formulation.

Compressible sugar consists mainly of sucrose that is processed to have properties suitable for direct compression. It also may contain small quantities of dextrin, starch, or invert sugar. It is a white crystalline powder with a sweet taste and complete water solubility. It requires the incorporation of a suitable lu-




Figure 45-13. (continued) d. Computer-controlled/monitored tableting.

bricant at normal levels for lubricity. The sugar is used widely for chewable vitamin tablets because of its natural sweetness. One commercial source is Di-Pac (*Amstar*) prepared by the cocrystallization of 97% sucrose and 3% dextrans. Some forms of lactose meet the requirements for a direct-compression vehicle. Hydrous lactose does not flow, and its use is limited to tablet formulations prepared by the wet-granulation method. Both anhydrous lactose and spray-dried lactose have good flowability and compressibility and can be used in direct compression provided a suitable disintegrant and lubricant are present. Mannitol is a popular diluent for chewable tablets because of its pleasant taste and mouth feel resulting from its negative heat of solution. In its granular form (*ICI Americas*) it has good flow and compressible qualities. It has a low moisture content and is not hygroscopic.

The excipient that has been studied extensively as a direct compression vehicle is microcrystalline cellulose (*Avicel, FMC*). This nonfibrous form of cellulose is obtained by spray-drying washed, acid-treated cellulose and is available in several grades that range in average particle size from 20 to 100 μm . It is water-insoluble, but the material has the ability to draw fluid into a tablet by capillary action; it swells on contact and thus acts as a disintegrating agent. The material flows well and has a degree of self-lubricating qualities, thus requiring a lower level of lubricant than other excipients.

Forced-flow feeders are mechanical devices, available from pharmaceutical equipment manufacturers, designed to deaerate light and bulky material. Mechanically, they maintain a steady flow of powder moving into the die cavities under moderate pressure. By increasing the density of the powder,

higher uniformity in tablet weights is obtained. See Figure 45-14.

Recently, many companies have reversed their optimism for some direct-compression systems. Some formulations made by direct compression were not as *forgiving* as the older wet-granulated products were. As raw material variations occurred, especially with the drug, many companies found themselves with poorly compactable formulations. Interest in direct compression also is stimulating basic research on the flowability of powders with and without additives.

Related Granulation Processes

SPHERONIZATION—Spheronization, a form of pelletization, refers to the formation of spherical particles from wet granulations. Since the particles are round, they have good flow properties when dried. They can be formulated to contain sufficient binder to impart cohesiveness for tableting. Spheronization equipment such as the Marumerizer (*Luwa*) and the CF-Granulator (*Vector*) are commercially available for small-scale manufacture, on up to commercial sized equipment. A wet granulation containing the drug substance, diluent (if required), and binder, is passed first through an extruding machine to form rod-shaped cylindrical segments ranging in diameter from 0.5 to 12 mm. The segment diameter and the size of the final spherical particle depend on the extruder screen size. After extrusion the segments are placed into the Marumerizer where they are shaped into spheres by centrifugal and frictional forces on a rotating plate (see Fig 45-15). The




Figure 45-14. Feeding devices designed to promote flow of granulations for high-speed machines (courtesy, Stokes/Pennwalt).

pellets then are dried by conventional methods, mixed with suitable lubricants, and compressed into tablets or used as capsule-fill material. Microcrystalline cellulose has been shown to be an effective diluent and binder in granulations to be spheronized.³⁵⁻³⁸ The advantages of the process include the production of granules, regular in shape, size, and surface characteristics; low friability resulting in fewer fines and less dust; and the ability to regulate the size of the spheres within a narrow particle-size distribution.

Spheres also can be produced by fluid-bed granulation techniques and by other specialized equipment such as the CF-Granulator (*Vector*). These processes, however, must begin with crystals or nonpareil seeds followed by buildup. Exact results, such as sphere density, are different for the various methods and could be important in product performance. These processes can be run as batches or continuously.

SPRAY-DRYING—A number of tableting additives suitable for direct compression have been prepared by the drying process known as spray-drying. The method consists of bringing together a highly dispersed liquid and a sufficient volume of hot air to produce evaporation and drying of the liquid droplets. The feed liquid may be a solution, slurry, emulsion, gel, or paste, provided it is pumpable and capable of being atomized. As shown in Figure 45-16, the feed is sprayed into a current of warm filtered air. The air supplies the heat for evaporation and



Figure 45-15. The inside of a QJ-400 Marumerizer (courtesy, Luwa).




Figure 45-16. Typical spray-drying system (courtesy, Bowen Eng).

conveys the dried product to the collector; the air is then exhausted with the moisture. As the liquid droplets present a large surface area to the warm air, local heat and transfer coefficients are high.

The spray-dried powder particles are homogeneous, approximately spherical in shape, nearly uniform in size, and frequently hollow. The latter characteristic results in low bulk density with a rapid rate of solution. Being uniform in size and spherical, the particles possess good flowability. The design and operation of the spray-dryer can vary many characteristics of the final product, such as particle size and size distribution, bulk and particle densities, porosity, moisture content, flowability, and friability. Among the spray-dried materials available for direct compression formulas are lactose, mannitol, and flour. Another application of the process in tableting is spray-drying the combination of tablet additives as the diluent, disintegrant, and binder. The spray-dried material then is blended with the active ingredient or drug, lubricated, and compressed directly into tablets.

Since atomization of the feed results in a high surface area, the moisture evaporates rapidly. The evaporation keeps the product cool and as a result the method is applicable for drying heat-sensitive materials. Among heat-sensitive pharmaceuticals successfully spray-dried are the amino acids; antibiotics as aureomycin, bacitracin, penicillin, and streptomycin; ascorbic acid; cascara extracts; liver extracts; pepsin and similar enzymes; protein hydrolysates; and thiamine.³⁹

Frequently, spray-drying is more economical than other processes, since it produces a dry powder directly from a liquid and eliminates other processing steps as crystallization, precipitation, filtering or drying, particle-size reduction, and particle classifying. By the elimination of these steps, labor, equipment costs, space requirements and possible contamination of the product are reduced. Intrinsic factor concentrate obtained from hog mucosa previously was prepared by *Lederle/American Home Products*, using a salt-precipitation process followed by a freeze-drying. By using spray-drying it was possible to manufacture a high-grade material by a continuous process. The spherical particles of the product facilitated its subsequent blending with vitamin B₁₂. Similar efficiencies have been found in processes producing magnesium trisilicate and dihydroxyaluminum sodium carbonate; both chemicals are used widely in antacid preparations.

Encapsulation of chemicals also can be achieved using spray-drying equipment. The process is useful in coating one material on another to protect the interior substance or to control the rate of its release. The substance to be coated can be either liquid or solid but must be insoluble in a solution of the coating material. The oil-soluble vitamins, A and D, can be coated with a variety of materials such as acacia gum to prevent their deterioration. Flavoring oils and synthetic flavors are coated to give the so-called dry flavors.

SPRAY-CONGEALING—Also called spray-chilling, spray-congealing is a technique similar to spray-drying. It consists of melting solids and reducing them to beads or powder by spraying the molten feed into a stream of air or other gas. The same basic equipment is used as with spray-drying, although




Figure 45-17. Concave punches.

no source of heat is required. Either ambient or cooled air is used, depending on the freezing point of the product. For example, monoglycerides and similar materials are spray-congealed with air at 50°F. A closed-loop system with refrigeration cools and recycles the air. Using this process, drugs can be dissolved or suspended in a molten wax and spray-congealed; the resultant material then can be adapted for a prolonged-release form of the drug.

Among the carbohydrates used in compressed tablets, mannitol is the only one that possesses high heat stability. Mannitol melts at 167° and, either alone or in combination with other carbohydrates, can be fused and spray-congealed. Selected drugs have been shown to be soluble in these fused mixtures, and the resultant spray-congealed material possesses excellent flow and compression characteristics.

TABLET MACHINES

As mentioned previously, the basic mechanical unit in tablet compression involves the operation of two steel punches within a steel die cavity. The tablet is formed by the pressure exerted on the granulation by the punches within the die cavity, or cell. The tablet assumes the size and shape of the punches and die used. See Figures 45-17 and 45-18. While round tablets are used more generally, oval, capsule-form, square, triangular, or other irregular shapes may be used. Likewise, the curvature of the faces of the punches determines the curvature of the tablets. The diameters generally found to be satisfactory and frequently referred to as standard are as follows: $\frac{3}{16}$, $\frac{1}{8}$, $\frac{1}{4}$, $\frac{3}{16}$, $\frac{1}{2}$, $\frac{3}{4}$, $\frac{1}{2}$, $\frac{3}{8}$, $\frac{1}{2}$, $\frac{3}{4}$, $\frac{1}{2}$, and $\frac{3}{4}$ in. Punch faces with ridges are used for compressed tablets scored for breaking into halves or fourths, although it has been indicated that variation among tablet halves is significantly greater than among intact tablets. However, a patented formulation⁴⁰ for a tablet scored to form a groove that is one-third to two-thirds the depth of the total tablet thickness is claimed to give equal parts containing substantially equal amounts of the drug substance. Tablets, engraved or embossed with symbols or initials, require punches with faces embossed or engraved with the corresponding designs. See Figures 45-19 and 45-20. The use of the tablet sometimes determines its shape; effervescent tablets are usually large, round, and flat, while vitamin tablets frequently are prepared in capsule-shaped forms. Tablets prepared using deep-cup punches appear to be round and when coated take on the appearance of pills. Veterinary tablets often have a bolus shape and are much larger than those used in medical practice.

The quality-control program for punches and dies, frequently referred to as tooling, instituted by large pharmaceuti-




Figure 45-18. Specially shaped punches.




Figure 45-19. Collection of punches (courtesy, Stokes/Pennwalt).

cal companies, emphasizes the importance of their care in modern pharmaceutical production. To produce physically perfect compressed tablets, an efficient punch-and-die program must be set up. Provisions for inspection of tooling, parameters for cost-per-product determination, product identification, and tooling specifications must all be considered. A committee of the Industrial and Pharmaceutical Technology Section of the APhA Academy of Pharmaceutical Sciences established a set of dimensional specifications and tolerances for standard punches and dies.⁴¹




Figure 45-20. Collection of dies (courtesy, Stokes/Pennwalt).

Regardless of the size of the tableting operation, the attention that must be given to the proper care of punches and dies should be noted. They must be highly polished and kept free from rust and imperfections. In cases in which the material pits or abrades the dies, chromium-plated dies have been used. Dropping the punches on hard surfaces will chip their fine edges. When the punches are in the machine, the upper and lower punches should not be allowed to contact each other; otherwise, a curling or flattening of the edges will result that is one of the causes of capping. This is especially necessary to observe in the case of deep-cup punches.

When the punches are removed from the machine, they should be washed thoroughly in warm soapy water and dried well with a clean cloth. A coating of grease or oil should be rubbed over all parts of the dies and punches to protect them from the atmosphere. They should be stored carefully in boxes or paper tubes.

Single-Punch Machines

The simplest tableting machines available are those having the single-punch design. A number of models are available as outlined in Table 45-2. While most of these are power-driven, several hand-operated models are available. Compression is accomplished on a single-punch machine as shown in Figure 45-21. The feed shoe filled with the granulation is positioned over the die cavity, which then fills. The feed shoe retracts and scrapes all excess granulation away from the die cavity. The upper punch lowers to compress the granulation within the die cavity. The upper punch retracts, and the lower punch rises to eject the tablet. As the feed shoe returns to fill the die cavity, it pushes the compressed tablet from the die platform. The weight of the tablet is determined by the volume of the die cavity; the lower punch is adjustable to increase or decrease the volume of granulation, thus increasing or decreasing the weight of the tablet.

For tablets having diameters larger than 1/2 inch, sturdier models are required. This is also true for tablets requiring a high degree of hardness, as in the case of compressed lozenges. The heavier models are capable of much higher pressures and are suitable for slugging.

OPERATION OF SINGLE-PUNCH MACHINES—In installing punches and dies in a single-punch machine, insert the lower punch first by lining up the notched groove on the punch with the lower punch setscrew and slipping it into the smaller bore in the die table; the setscrew is not tightened yet. The lower punch is differentiated from the upper punch in that it has a collar around the punch head. Slip the die over the punch head so that the notched groove (with the widest area at the top) lines up with the die setscrew. Tighten the lower punch setscrew after seating the lower punch by pressing on the punch with the thumb. Tighten the die setscrew, making certain that the surface of the die is flush with the die table. Insert the upper punch, again lining up the grooved notch with the upper punch setscrew. To be certain that the upper punch is seated securely, turn the machine over by hand with a block of soft wood or wad of cloth between the upper and lower punches. When the punch is seated, tighten the upper punch setscrew. Adjust the pressure so that the upper and lower punches will not come

Table 45-2. Single-Punch Tablet Machines

MACHINE MODEL	MAXIMUM TABLET DIAMETER (INCHES)	PRESS SPEED (TABLETS/MIN)	DEPTH OF FILL (INCHES)
Stokes-Pennwalt equipment^a			
511-5	1/2	40–75	7/16
206-4	1 3/4	10–40	1 1/16
530-1	2	12–48	1 1/8
525-2	3	16–48	2
Manesty equipment (Thomas Eng)			
Hand machine	1/2	100	7/16
Model F3	3/8	85	1 1/16
Model 35T ^a	3	36	2 1/4

^a Widely used for veterinary boluses.




Figure 45-21. The steps associated with single-punch and rotary tablet machines.

in contact with each other when the machine is turned over. Adjust the lower punch so that it is flush with the die table at the ejection point. Install the feed shoe and hopper.

After adding a small amount of granulation to the hopper, turn the machine over by hand and adjust the pressure until a tablet is formed. Adjust the tablet weight until the desired weight is obtained. The pressure will have to be altered concurrently with the weight adjustments. It should be remembered that as the fill is increased the lower punch moves farther away from the upper punch, and more pressure will have to be applied to obtain comparable hardness. Conversely, when the fill is decreased, the pressure will have to be decreased. When all the adjustments have been made, fill the hopper with granulation and turn on the motor. Hardness and weight should be checked immediately, and suitable adjustments made if necessary. Periodic checks should be made on the tablet hardness and weight during the running of the batch, at 15- to 30-min intervals.

When the batch has been run off, turn off the power and remove loose dust and granulation with the vacuum cleaner. Release the pressure from the punches. Remove the feed hopper and the feed shoe. Remove the upper punch, the lower punch, and the die. Clean all surfaces of the tablet machine, and dry well with clean cloth. Cover surfaces with thin coating of grease or oil prior to storage.

As tablets are ejected from the machine after compression, they usually are accompanied by powder and uncompressed granulation. To remove this loose dust, the tablets are passed over a screen, which may be vibrating, and cleaned with a vacuum line.

Rotary Tablet Machines

For increased production, rotary machines offer great advantages. A head carrying a number of sets of punches and dies revolves continuously while the tablet granulation runs from the

hopper, through a feed frame and into the dies placed in a large, steel plate revolving under it. This method promotes a uniform fill of the die and therefore an accurate weight for the tablet. Compression takes place as the upper and lower punches pass between a pair of rollers, as can be seen in Figure 45-21. This action produces a slow squeezing effect on the material in the die cavity from the top and bottom and so gives a chance for the entrapped air to escape. The lower punch lifts up and ejects the tablet. Adjustments for tablet weight and hardness can be made without the use of tools while the machine is in operation. Figure 45-22 shows a high speed press. Figure 45-23 shows the tooling in a 16-station rotary press in the positions of a complete cycle to produce 1 tablet per set of tooling. One of the factors that contributes to the variation in tablet weight and hardness during compression is the internal flow of the granulation within the feed hopper.

On most rotary machine models there is an excess pressure release that cushions each compression and relieves the machine of all shocks and undue strain. The punches and dies can be removed readily for inspection, cleaning, and inserting different sets to produce a great variety of sizes and shapes. Many older presses have been modernized with protective shields to prevent physical injury and to comply with OSHA standards (Fig 45-24). It is possible to equip the machine with as few punches and dies as the job requires and thus economize on installation costs. For types of rotary machines available, see Table 45-3.

OPERATION OF ROTARY MACHINES—Before inserting punches and dies, make certain that the pressure has been released from the pressure wheel. The die holes should be cleaned thoroughly, making certain that the die seat is completely free of any foreign materials. Back off all die locks, and loosely insert dies into the die holes, then tap each die securely into place with a fiber of soft metal rod through the upper punch holes. After all the dies have been tapped into place, tighten each die lock screw progressively and securely. As each screw is tightened the die is checked to see that it does not project above the die table. Insert the lower punches through the hole made available by removing the punch head. Turn the machine by hand until the punch bore coincides with the plug hole. Insert each lower punch in its place progressively. Insert the upper punches by




Figure 45-22. Model 747 High Speed Press, double-sided rotary compacting press designed to produce at speeds over 10,000/min (courtesy, Stokes/Pennwalt).




Figure 45-23. Tooling for a 16-station rotary press showing positions of the cycle required to produce one tablet per set of tooling (courtesy, Vector/Colton).

dropping them into place in the head. Each punch (upper and lower) should be coated with a thin film of mineral oil before insertion into the machine. Adjust the ejection cam so that the lower punch is flush with the die table at the ejection point.

After insertion of the punches and dies, adjust the machine for the tablet weight and hardness. The feed frame should be attached to the machine along with the feed hopper. Add a small amount of the granulation through the hopper and turn over the machine by hand. Increase the pressure by rotating the pressure wheel until a tablet is formed. Check the weight of the tablet and adjust the fill to provide the desired tablet weight. Most likely more than one adjustment of the fill will be necessary before obtaining the acceptable weight. When the fill is decreased, the pressure must be decreased to provide the same hardness in the tablet. Conversely, when the fill is increased, the pressure must be increased to obtain comparable hardness.

Fill the hopper with the granulation and turn on the power. Check tablet weight and hardness immediately after the mechanical operation begins, and make suitable adjustments, if necessary. Check these properties routinely and regularly at 15- to 30-min intervals while the machine is in operation. When the batch has been run, turn off the power. Remove the hopper and feed frame from the machine. Remove loose granulation and dust with a vacuum line. Remove all pressure from the wheel. Remove the punches and dies in the reverse order of that used in setting up the machine. First, remove the upper punches individually,



Figure 45-24. Research technicians use an instrumented tablet press to develop processes at Schering-Plough.

Table 45-3. High-Speed Rotary Tablet Machines

MACHINE MODEL	TOOL SETS	MAXIMUM TABLET DIAMETER (INCHES)	PRESS SPEED (TABLETS/MIN)	DEPTH OF FILL (INCHES)	MACHINE MODEL	TOOL SETS	MAXIMUM TABLET DIAMETER (INCHES)	PRESS SPEED (TABLETS/MIN)	DEPTH OF FILL (INCHES)
Vector-Colton equipment					Stokes/Pennwalt equation				
2216	16	$\frac{5}{8}$	1180	$\frac{3}{4}$	552-2	35	$\frac{5}{8}$	800–3200	$\frac{1}{16}$
240	16	$\frac{7}{8}$	640	$\frac{13}{16}$	328-4	45	$\frac{3}{4}$	1600–4500	$1\frac{3}{8}$
250	12	$1\frac{1}{4}$	480	$1\frac{1}{8}$	610	65	$\frac{7}{16}$	3500–10,000	$\frac{1}{16}$
260	25	$1\frac{3}{16}$	1450	$1\frac{3}{8}$	747	65	$\frac{7}{16}$	3000–10,000	$\frac{1}{16}$
	31	1	1800	$1\frac{3}{8}$		53	$\frac{5}{8}$	2900–8100	$\frac{1}{16}$
	33	$\frac{15}{16}$	1910	$1\frac{3}{8}$		41	$\frac{15}{16}$	2150–6150	$\frac{1}{16}$
	43	$\frac{5}{8}$	2500	$1\frac{3}{8}$	Direct Triple Compression Type				
270	25	$1\frac{3}{8}$	450	$2\frac{3}{4}$	580-1	45	$\frac{7}{16}$	525–2100	$\frac{1}{16}$
Stokes/Pennwalt equipment					580-2	35	$\frac{5}{8}$	400–1600	$\frac{1}{16}$
Manesty equipment (Thomas Eng)					610	65	$\frac{7}{16}$	3500–10,000	$\frac{1}{16}$
B3B	16	$\frac{5}{8}$	350–700	$\frac{1}{16}$		53	$\frac{5}{8}$	2900–8100	$\frac{1}{16}$
	23	$\frac{7}{16}$	500–1000	$\frac{1}{16}$	Manesty equipment (Thomas Eng)				
BB3B	27	$\frac{5}{8}$	760–1520	$\frac{1}{16}$	Betapress	16	$\frac{5}{8}$	600–1500	$\frac{1}{16}$
	33	$\frac{7}{16}$	924–1848	$\frac{1}{16}$		23	$\frac{7}{16}$	860–2160	$\frac{1}{16}$
	35	$\frac{5}{8}$	1490–2980	$\frac{1}{16}$	Express	20	1	800–2000	$\frac{13}{16}$
	45	$\frac{7}{16}$	1913–3826	$\frac{1}{16}$		25	$\frac{5}{8}$	1000–2500	$\frac{1}{16}$
D3B	16	1	260–520	$\frac{13}{16}$		30	$\frac{7}{16}$	1200–3000	$\frac{1}{16}$
Key equipment					Unipress	20	1	970–2420	$\frac{13}{16}$
DC-16	16	$\frac{15}{16}$	210–510	$\frac{13}{16}$		27	$\frac{5}{8}$	1300–3270	$\frac{1}{16}$
BBC	27	$\frac{5}{8}$	1025–2100	$\frac{1}{16}$		34	$\frac{7}{16}$	1640–4120	$\frac{1}{16}$
	35	$\frac{5}{8}$	1325–2725	$\frac{1}{16}$	Novapress	37	1	760–3700	$\frac{13}{16}$
	45	$\frac{7}{16}$	1700–3500	$\frac{1}{16}$		45	$\frac{5}{8}$	900–4500	$\frac{1}{16}$
Cadpress	37	$\frac{15}{16}$	850–3500	$\frac{13}{16}$		61	$\frac{7}{16}$	1220–6100	$\frac{1}{16}$
	45	$\frac{5}{8}$	2000–6000	$\frac{1}{16}$	BB3B	35	$\frac{5}{8}$	1490–2980	$\frac{1}{16}$
	55	$\frac{7}{16}$	2500–7500	$\frac{1}{16}$	BB4	27	$\frac{5}{8}$	900–2700	$\frac{1}{16}$
Fette equipment (Raymond Auto)						35	$\frac{5}{8}$	1167–3500	$\frac{1}{16}$
		(mm)		(mm)		45	$\frac{7}{16}$	1500–4500	$\frac{1}{16}$
Perfecta 1000	28	16	2100	18	Rotapress				
	33	13	2475	18	Mark IIA	37	1	710–3550	$\frac{13}{16}$
Perfecta 2000	29	25	2175	22		45	$\frac{5}{8}$	1640–8200	$\frac{1}{16}$
	36	16	3600	18		61	$\frac{7}{16}$	2200–11,100	$\frac{1}{16}$
	43	13	4300	18	Mark IV	45	1	2090–6000	$\frac{13}{16}$
Courtroy equipment (AC Compact)						55	$\frac{5}{8}$	2550–7330	$\frac{1}{16}$
R-100	24	25	285–2260	20		75	$\frac{7}{16}$	3500–10,000	$\frac{1}{16}$
	30	19	356–2850	20	Fette tool systems				
	36	13	550–440	16			(mm)		(mm)
Kikusui equipment					PT 2080	29	25	435–2900	18
Hercules	18	37	180–540	16		36	16	540–4100	18
	21	26	210–630	16		43	16	645–4900	18
	29	25	290–870	16	PT 2090IC	22	34	1760	18
Virgo	19	16	418–1330	16		29	25	2900	18
	24	11	528–1680	16		36	16	4140	18
Killian equipment						43	13	5160	18
TX21	21	28	231–1386	20		47	11	6110	18
TX25	25	22	275–2166	20	PT 3090IC	37	34	5920	18
TX30	30	16	330–3150	20		49	25	7840	18
TX21D	21	25	231–1826	20		61	16	9760	18
TX30A	30	16	330–3150	16	P 3100	37	25	5618	22
TX40A	40	13	440–4200	16		45	16	8100	18
Korsch equipment						55	13	9900	18
PH 250/20	20	25	240–1640	22	Courtroy equipment (AC Compact)				
PH 250/25	25	16	270–2700	18	R-200	43	25	750–5833	20
PH 250/30	30	13	315–3233	18		55	19	916–8500	20
Elizabeth-Hata equipment						65	13	1083–10,000	16
AP-15-SSU	15	17	300–1050	8–18	Kikusui equipment				
AP-18-SSU	18	13	360–1260	8–18	Libra	36	16	900–2520	16
AP-22-SSU	22	11	440–1540	8–18		45	11	1125–3150	16
AP-32-SSU	32	17	640–2240	8–18		49	8	1225–3430	16
AP-38-MSU	38	13	760–2660	8–18	Gemini	55	16	2200–7700	16
AP-45-MSU	32	11	900–3150	8–18		67	11	2680–9380	16
Vector-Colton equipment						73	8	2920–10,200	16
2247	33	$\frac{5}{8}$	3480	$\frac{3}{4}$	Elizabeth-Hata equipment				
	41	$\frac{7}{16}$	4300	$\frac{3}{4}$	AP-45-LDU	45	17	1800–6300	8–18
	49	$\frac{7}{16}$	5150	$\frac{3}{4}$	AP-55-LDU	55	13	2200–7700	8–18
Magna	66	$2\frac{7}{32}$	10,560	$\frac{3}{4}$	AP-65-LDU	65	11	2600–9100	8–18
	74	$\frac{1}{2}$	11,840	$\frac{3}{4}$	AP-71-LDU	71	11	2840–9940	8–18
	90	$\frac{7}{16}$	14,400	$\frac{3}{4}$	51-XLDU	51	17	2040–7140	8–18
					65-XLDU	61	13	2440–8540	8–18

then the lower punches, and finally the dies. Wash each punch and die in alcohol and brush with a soft brush to remove adhering material. Dry them with a clean cloth, and cover them with a thin coating of grease or oil before storing.

High-Speed Rotary Tablet Machines

The rotary tablet machine has evolved gradually into models capable of compressing tablets at high production rates. See Figures 45-22, 45-25, and 45-26. This has been accomplished by increasing the number of stations, ie, sets of punches and dies, in each revolution of the machine head, improving feeding devices, and on some models installing dual compression points. In Figure 45-26, the drawing shows a rotary machine with dual compression points. Rotary machines with dual compression points are referred to as double rotary machines, and those with one compression point, single rotary. In the diagram, half of the tablets are produced 180° from the tablet chute. They travel outside the perimeter and discharge with the second tablet production. While these models are mechanically capable of operating at the production rates shown in Table 45-3, the actual speed still depends on the physical characteristics of the tablet granulation and the rate that is consistent with compressed tablets having satisfactory physical characteristics. The main difficulty in rapid machine operation is ensuring adequate filling of the dies. With rapid filling, dwell time of the die cavity beneath the feed frame is insufficient to ensure the requirements of uniform flow and packing of the dies. Various methods of force-feeding the granulation into the dies have been devised to refill the dies in the very short dwell time permitted on the high-speed machine. These devices are illustrated in Figure 45-14. Presses with triple compression points (see Table 45-3) permit the partial




Figure 45-25. Rotapress Mark IIA. Designed for improvements in sound reduction, operator safety, cleanliness, and operational convenience; note the control panel on front of machine (courtesy, Thomas/Manesty).




Figure 45-26. The movement of tablets on die table of a double rotary press (courtesy, Vector/Colton).

compaction of material before final compaction. This provides for partial deaeration and particle orientation of material before final compression. This helps in the direct compacting of materials and reduces laminating and capping due to entrapped air.

Multilayer Rotary Tablet Machines

The rotary tablet machines also have been developed into models capable of producing multiple-layer tablets; the machines are able to make 1-, 2-, or 3-layer tablets (Versa Press, Stokes/Pennwalt). Stratified tablets offer a number of advantages. Incompatible drugs can be formed into a single tablet by separating the layers containing them with a layer of inert material. It has permitted the formulation of time-delay medication and offers a wide variety of possibilities in developing color combinations that give the products identity.

Originally, the tablets were prepared by a single-compression method. The dies were filled with the different granulations in successive layers, and the tablet was formed by a single compression stroke. The separation lines of the tablets prepared by this method tended to be irregular. In the machines now available for multilayer production the granulation receives a precompression stroke after the first and second fill, which lightly compacts the granulation and maintains a well-defined surface of separation between each layer. The operator is able to eject either precompressed layer with the machine running at any desired speed for periodic weight and analysis checks.

Other multiple-compression presses can receive previously compressed tablets and compress another granulation around the preformed tablet. An example of a press with this capability is the Manesty Drycota (Thomas/Manesty). Pressure-coated tablets can be used to separate incompatible drug substances and also to give an enteric coating to the core tablets.

Capping and Splitting of Tablets

The splitting or capping of tablets is one of great concern and annoyance in tablet making. It is quite difficult to detect while the tablets are being processed but can be detected easily by vigorously shaking a few in the cupped hands. A slightly chipped tablet does not necessarily mean that the tablet will cap or split.

There are many factors that may cause a tablet to cap or split:

Excess *fines* or powder, which traps air in the tablet mixture.

Deep markings on tablet punches. Many designs or *scores* on punches are too broad and deep. Hairline markings are just as appropriate as deep, heavy markings.



Figure 45-27. Courtoy R-100 with computer-controlled operation.

Worn and imperfect punches. Punches should be smooth and buffed. Nicked punches often cause capping. The development of fine feather edges on tablets indicates wear on punches.

Worn dies. Dies should be replaced or reversed. Dies that are chrome-plated or have tungsten carbide inserts wear longer and give better results than ordinary steel dies.

Too much pressure. By reducing the pressure on the machines the condition may be corrected.

Unsuitable formula. It may be necessary to change the formula.

Moist and soft granulation. This type of granulation will not flow freely into the dies, thus giving uneven weights and soft or capped tablets.





Figure 45-28. Direct weighing of tablets produced gives actual weight feedback for the controller of the Courtoy R-100 (seen in the bottom left of Fig 45-27).

SPRING – COMPENSATED ROTARY PRESS SIGNAL



AIR – COMPENSATED ROTARY PRESS SIGNAL




Figure 45-29. Force-time curves for two types of tablet press.

Poorly machined punches. Uneven punches are detrimental to the tablet machine itself and will not produce tablets of accurate weight. One punch out of alignment may cause one tablet to split or cap on every revolution.

Instrumented Tablet Presses

Compressional and ejectional forces involved in tablet compression can be studied by attaching strain gauges to the punches and other press components involved in compression. The electrical output of the gauges has been monitored by telemetry or use of a dual-beam oscilloscope equipped with camera.^{42,43} Instrumentation permits a study of the compaction characteristics of granulations, their flowabilities, and the effect of formulation additives, such as lubricants, as well as differences in tablet press design, as shown in Figures 45-27 to 45-30. Physical characteristics of tablets, such as hardness, friability, disintegration time, and dissolution rate, are influenced not only by the nature of the formulation but by the compressional force as well.

As can be seen in Figures 45-29 and 45-30, the rate and duration of compaction forces can be quantified. The rate of force application has a profound effect on powder consolidation within the die and, hence, efficiency of packing and powder compaction. The rate of release of force, or *decompression* has




Figure 45-30. Plot showing the upper and lower punch forces as functions of the position of the punch face within the die. A biaxial force/displacement curve also shown is a plot of the position of the tablet center as a function of the compression force.




Figure 45-31. Schematic of an instrumentation system using a micro-computer as developed by Schering-Plough.

a direct effect on the ability of the tablet to withstand relaxation. A prominent hypothesis, fostered by Hiestand^{44,45} and later Luenberger⁴⁶, suggested that capping and laminating of tablets is caused by too-rapid stress relaxation or decompression. This explains why slowing a tablet press and using tapered dies is useful in such situations. Most prominent pharmaceutical scientists have embraced this theory and largely have discounted air entrapment as a cause of capping and laminating.

Figure 45-30 presents an interesting set of plots. Walter and Augsburg reported that as compaction force rises, the steel tooling actually compresses in accommodation to the forces applied. The forces used to produce a tablet are considerable and should be monitored and understood.⁴⁷ Therefore, definition of the compressional force and duration of force (dwell time) giving a satisfactory tablet for a formulation provides an in-process control for obtaining both tablet-to-tablet and lot-to-lot uniformity (see Figs 45-24 and 45-31).

Instrumentation has led to the development of on-line, automatic, electromechanical tablet weight-control systems capable of continuously monitoring the weights of tablets as they are produced. Units are available commercially (Thomas Tablet Sentinel (*Thomas Eng*); Fette Compression Force Monitor (*Raymond Auto*); Vali-Tab (*Stokes/Pennwalt*)) and are applicable to single or rotary tablet machines. Most commercial presses today can be delivered with some sort of instrumentation attached. When tablet weights vary from preset limits, the monitor automatically will adjust the weight control mechanism to reestablish weights within acceptable limits. If the difficulty continues, the unit will activate an audible warning signal or an optional shut-down relay on the press (see Figs 45-27 and 45-28). Most production-model tablet presses come equipped with complete instrumentation (optional) and with options for statistical analysis and print out of compression/ejection signals. The techniques and applications of press instrumentation have been reviewed.^{48,49}

Contamination Control

While good manufacturing practices used by the pharmaceutical industry for many years have stressed the importance of cleanliness of equipment and facilities for the manufacture of drug products, the penicillin contamination problem resulted in renewed emphasis on this aspect of manufacturing. Penicillin, as either an airborne dust or residual quantities remaining in equipment, is believed to have contaminated unrelated products in sufficient concentrations to cause allergic reactions in individuals hypersensitive to penicillin who received these products. This resulted in the industry spending millions of dollars to change or modify buildings, manufacturing processes, equipment, and standard operating procedures to eliminate penicillin contamination.

With this problem has come renewed emphasis on the dust problem, material handling, and equipment cleaning in dealing with drugs, especially potent chemicals. Any process using chemicals in powder form can be a dusty operation; the preparation of compressed tablets and encapsulation fall in this category. In the design of tablet presses attention is being given to the control and elimination of dust generated in the tableting process. In the Perfecta press shown in Figure 45-32, the pressing compartment is completely sealed off from the outside environment, making cross-contamination nearly impossible. The pressing compartment can be kept dust-free by the air supply and vacuum equipment developed for the machine. It removes airborne dust and granular particles that have not been compressed, thus keeping the circular pressing compartment and the upper and lower punch guides free of dust.

Drug manufacturers have the responsibility to make certain that microorganisms present in finished products are unlikely to cause harm to the patient and will not be deleterious to the product. An outbreak of *Salmonella* infections in Scandinavian countries was traced to thyroid tablets that had been prepared from contaminated thyroid powder. This concern eventually led to the establishment of microbial limits for raw materials of animal or botanical origin, especially those that readily support microbial growth and are not rendered sterile during subsequent processing. Harmful microorganisms when present in oral products include *Salmonella* spp, *Escherichia coli*, certain *Pseudomonas* spp such as *P. aeruginosa*, and *Staphylococcus aureus*. The compendia have microbial limits on raw materials such as aluminum hydroxide gel, cornstarch, thyroid, acacia, and gelatin.

These represent examples of the industry's efforts to conform with the intent of current good manufacturing practice as defined by the FDA.



Figure 45-32. Fette Perfecta 3000 high-speed tablet press with pressing compartment completely sealed off from outside environment, making cross-contamination impossible (courtesy, Raymond Auto).

Tablet Formulations

WET GRANULATION

CT Acetaminophen, 300 mg

INGREDIENTS	IN EACH	IN 10,000
Acetaminophen	300 mg	3000 g
Polyvinylpyrrolidone	22.5 mg	225 g
Lactose 61.75 mg 617.5 g		
Alcohol SD3A—200 proof	4.5 mL	45 L
Stearic acid	9 mg	90 g
Talc	13.5 mg	135 g
Cornstarch	43.25 mg	432.5 g

Blend acetaminophen, polyvinylpyrrolidone, and lactose together; pass through a 40-mesh screen. Add the alcohol slowly, and knead well. Screen the wet mass through a 4-mesh screen. Dry the granulation at 50° overnight. Screen the dried granulation through a 20-mesh screen. Bolt the stearic acid, talc, and cornstarch through a 60-mesh screen prior to mixing by tumbling with the granulation. Compress, using 7/16-inch standard concave punch. Ten tablets should weigh 4.5 g (courtesy, Abbott).

CT Ascorbic Acid USP, 50 mg

INGREDIENTS	IN EACH	IN 7000
Ascorbic acid USP (powder No. 80) ^a	55 mg	385 g
Lactose	21 mg	147 g
Starch (potato)	13 mg	91 g
Ethylcellulose N 100 (80–105 cps)	16 mg	112 g
Starch (potato)	7 mg	49 g
Talc	6.5 mg	45.5 g
Calcium stearate (impalpable powder) ¹ 1 mg		7 g
Weight of granulation		836.5 g

^a Includes 10% in excess of label claim.

Granulate the first three ingredients with ethylcellulose (5%) dissolved in anhydrous ethyl alcohol, adding additional anhydrous alcohol to obtain good, wet granules. Wet-screen through a #8 stainless steel screen and dry at room temperature in an air-conditioned area. Dry-screen through a #20 stainless steel screen and incorporate the remaining three ingredients. Mix thoroughly and compress. Use a flat, beveled, ¼-inch punch. Twenty tablets should weigh 2.39 g.

Chewable Antacid Tablets

INGREDIENTS	IN EACH	IN 10,000
Magnesium trisilicate	500 mg	5000 g
Aluminum hydroxide, dried gel	250 mg	2500 g
Mannitol	300 mg	3000 g
Sodium saccharin	2 mg	20 g
Starch paste, 5%	qs	qs
Oil of peppermint	1 mg	10 g
Magnesium stearate	10 mg	100 g
Cornstarch	10 mg	100 g

Mix the magnesium trisilicate and aluminum hydroxide with the mannitol. Dissolve the sodium saccharin in a small quantity of purified water, then combine this with the starch paste. Granulate the powder blend with the starch paste. Dry at 140°F and screen through 16-mesh screen. Add the flavoring oil, magnesium stearate, and corn starch; mix well. Age the granulation for at least 24 hr and compress, using a ¾-inch, flat-face, bevel-edge punch (courtesy, Atlas).

CT Hexavitamin

INGREDIENTS	IN EACH	IN 7000
Ascorbic acid USP (powder) ^a	82.5 mg	577.5 g
Thiamine mononitrate USP (powder) ^a	2.4 mg	16.8 g
Riboflavin ^a	3.3 mg	23.1 g
Nicotinamide USP (powder) ^a	22 mg	154 g
Starch	13.9 mg	97.4 g
Lactose	5.9 mg	41.2 g
Zein	6.4 mg	45 g
Vitamin A acetate	6250 U	
Vitamin D ₂ ^a (use Pfizer crystals medium granules containing 500,000 U vitamin A acetate and 50,000 U vitamin D ₂ /g)	625 U	87.5 g
Magnesium stearate		7.5 g
Weight of granulation		1050 g

^a Includes the following in excess of label claim: ascorbic acid 10%, thiamine mononitrate 20%, riboflavin 10%, nicotinamide 10%, and vitamin A acetate–vitamin D₂ crystals 25%.

Thoroughly mix the first six ingredients and granulate with zein (10% in ethyl alcohol, adding additional alcohol if necessary to obtain good, wet granules). Wet-screen through a #8 stainless steel screen and dry at 110 to 120°F. Dry-screen through a #20 stainless steel screen and add the vitamin crystals. Mix thoroughly, lubricate, and compress. Ten tablets should weigh 1.50 g. Coat with syrup.

CT Theobromine-Phenobarbital

INGREDIENTS	IN EACH	IN 7000
Theobromine	325 mg	2275 g
Phenobarbital	33 mg	231 g
Starch	39 mg	273 g
Talc	8 mg	56 g
Acacia (powder)	8 mg	56 g
Stearic acid	0.7 mg	4.9 g
Weight of granulation		2895.9 g

Prepare a paste with the acacia and an equal weight of starch. Use this paste for granulating the theobromine and phenobarbital. Dry and put through a 12-mesh screen, add the remainder of the material, mix thoroughly, and compress into tablets, using a 13/32-inch concave punch. Ten tablets should weigh 4.13 g.

FLUID-BED GRANULATION

CT Ascorbic Acid USP, 50 mg

INGREDIENTS	IN EACH	IN 10,000
Ascorbic acid USP (powder no 80) ^a	55 mg	550 g
Lactose	21 mg	210 g
Starch (potato)	13 mg	130 g
Ethylcellulose N100 (80–105 cps)	16 mg	160 g
Starch (potato)	7 mg	70 g
Talc	6.5 mg	65 g
Calcium stearate	1 mg	10 g
Weight of granulation		1195.0 g

^a Includes 10% in excess of claim.

Add the first three ingredients to the granulator. Mix for 5 to 15 min or until well mixed. Dissolve the ethylcellulose in anhydrous ethanol and spray this solution and any additional ethanol into the fluidized mixture. Cease spraying when good granules are produced. Dry to approximately 3% moisture. Remove the granules and place them in a suitable blender. Sequentially add the remaining three ingredients with mixing steps in between each addition. Compress, using a flat, beveled, 1/4-inch punch. Twenty tablets should weigh 2.39 g.

Sustained-Release (SR) Procainamide Tablets

INGREDIENTS	IN EACH	IN 10,000
Procainamide	500 mg	5000 g
HPMC 2208, USP	300 mg	3000 g
Carnauba wax	60 mg	600 g
HPMC 2910, USP	30 mg	300 g
Magnesium stearate	4 mg	40 g
Stearic acid	11 mg	110 g
Talc	5 mg	50 g
Weight of granulation		9100 g

Place the first three ingredients in the granulator and mix for 5 to 15 min. Dissolve the HPMC in water (mix in hot water, then cool down) and spray into the fluidized mixture. Dry to approximately 5% moisture. Sequentially add the last three ingredients, with mixing steps in between each addition. Compress, using capsule-shaped tooling. Ten tablets should weigh 9.1 g.

DRY GRANULATION**CT Acetylsalicylic Acid**

INGREDIENTS	IN EACH	IN 7000
Acetylsalicylic Acid (crystals 20-mesh)	0.325 g	2275 g
Starch		226.8 g
Weight of granulation		2501.8 g

Dry the starch to a moisture content of 10%. Thoroughly mix this with the acetylsalicylic acid. Compress into slugs. Grind the slugs to 14- to 16-mesh size. Recompress into tablets, using a $\frac{1}{8}$ -inch punch. Ten tablets should weigh 3.575 g.

CT Sodium Phenobarbital

INGREDIENTS	IN EACH	IN 7000
Phenobarbital sodium	65 mg	455 g
Lactose (granular, 12-mesh)	26 mg	182 g
Starch	20 mg	140 g
Talc	20 mg	140 g
Magnesium stearate	0.3 mg	2.1 g
Weight of granulation		919.1 g

Mix all the ingredients thoroughly. Compress into slugs. Grind and screen to 14- to 16-mesh granules. Recompress into tablets, using a $\frac{1}{8}$ -inch concave punch. Ten tablets should weigh 1.3 g.

CT Vitamin B Complex

INGREDIENTS	IN EACH	IN 10,000
Thiamine mononitrate ^a	0.733 mg	7.33 g
Riboflavin ^a	0.733 mg	7.33 g
Pyridoxine hydrochloride	0.333 mg	3.33 g
Calcium pantothenate ^a	0.4 mg	4 g
Nicotinamide	5 mg	50 g
Lactose (powder)	75.2 mg	752 g
Starch	21.9 mg	219 g
Talc	20 mg	200 g
Stearic acid (powder)	0.701 mg	7.01 g
Weight of granulation		1250 g

^a Includes 10% in excess of label claim.

Mix all the ingredients thoroughly. Compress into slugs. Grind and screen to 14- to 16-mesh granules. Recompress into tablets, using a $\frac{1}{8}$ -inch concave punch. Ten tablets should weigh 1.25 g. Sufficient tartaric acid should be used in these tablets to adjust the pH to 4.5.

DIRECT COMPRESSION**APC Tablets**

INGREDIENTS	IN EACH	IN 10,000
Aspirin (40-mesh crystal)	224 mg	2240 g
Phenacetin	160 mg	1600 g
Caffeine (anhyd USP gran)	32 mg	320 g
Compressible sugar (Di-Pac ^a)	93.4 mg	934 g
Sterotex	7.8 mg	78 g
Silica gel (Syloid 244 ^b)	2.8 mg	28 g

^a Amstar.

^b Davison Chem.

Blend ingredients in a twin-shell blender for 15 min and compress on a $\frac{1}{32}$ -inch standard concave punch (courtesy, Amstar).

CT Ascorbic Acid USP, 250 mg

INGREDIENTS	IN EACH	IN 10,000
Ascorbic Acid USP (Merck, fine crystals)	255 mg	2550 g
Microcrystalline cellulose ^a	159 mg	1590 g
Stearic acid	9 mg	90 g
Colloidal silica ^b	2 mg	20 g
Weight of granulation		4250 g

^a Avicel-PH-101.

^b Cab-O-Sil.

Blend all ingredients in a suitable blender. Compress, using $\frac{1}{16}$ -inch standard concave punch. Ten tablets should weigh 4.25 g (courtesy, FMC).

Breath Freshener Tablets

INGREDIENTS	IN EACH	IN 10,000
Wintergreen oil	0.6 mg	6 g
Menthol	0.85 mg	8.5 g
Peppermint oil	0.3 mg	3 g
Silica gel (Syloid 244 ^a)	1 mg	10 g
Sodium saccharin	0.3 mg	3 g
Sodium bicarbonate	14 mg	140 g
Mannitol USP (granular)	180.95 mg	1809.5 g
Calcium stearate	2 mg	20 g

^a Davison Chem.

Mix the flavor oils and menthol until liquid. Adsorb onto the silica gel. Add the remaining ingredients. Blend and compress on $\frac{3}{16}$ -inch, flat-face bevel-edge punch to a thickness of 3.1 mm (courtesy, Atlas).

Chewable Antacid Tablets

INGREDIENTS	IN EACH	IN 10,000
Aluminum hydroxide and magnesium carbonate, codried gel ^a	325 mg	3250 g
Mannitol USP (granular)	675 mg	6750 g
Microcrystalline cellulose ^b	75 mg	750 g
Corn starch	30 mg	300 g
Calcium stearate	22 mg	220 g
Flavor	qs	qs

^a Reheis F-MA-11.

^b Avicel

Blend all ingredients in a suitable blender. Compress, using a 5/8-inch, flat-face, bevel-edge punch (courtesy, Atlas).

Chewable Multivitamin Tablets

INGREDIENTS	IN EACH	IN 10,000
Vitamin A USP (dry, stabilized form)	5000 USP units	50 million units
Vitamin D dry, stabilized form)	400 USP units	4 million units
Ascorbic Acid USP	60.0 mg	600 g
Thiamine Hydrochloride USP	1 mg	10 g
Riboflavin USP	1.5 mg	15 g
Pyridoxine Hydrochloride USP	1 mg	10 g
Cyanocobalamin USP	2 µg	20 mg
Calcium Pantothenate USP	3 mg	30 g
Niacinamide USP	10 mg	100 g
Mannitol USP (granular)	236.2 mg	2362 g
Cornstarch	16.6 mg	166 g
Sodium saccharin	1.1 mg	11 g
Magnesium stearate	6.6 mg	66 g
Talc USP	10 mg	100 g
Flavor	qs	qs

Blend all ingredients in a suitable blender. Compress, using a $\frac{3}{16}$ -inch, flat-face, bevel-edge punch (courtesy, *Atlas*).

CT Ferrous Sulfate

INGREDIENTS	IN EACH	IN 7000
Ferrous Sulfate USP (crystalline)	0.325 g	2275 g
Talc		0.975 g
Sterotex		1.95 g
Weight of granulation		2277.93 g

Grind to 12- to 14-mesh, lubricate, and compress. Coat immediately to avoid oxidation to the ferric state with 0.410 gr of tolu balsam (dissolved in alcohol) and 0.060 gr of salol and chalk. Use a deep, concave, $\frac{1}{32}$ -inch punch. Ten tablets should weigh 3.25 g.

CT Methenamine

INGREDIENTS	IN EACH	IN 7000
Methenamine (12- to 14-mesh crystals)	0.325 g	2275 g
Weight of granulation		2275 g

Compress directly, using a $\frac{3}{16}$ -inch punch. Ten tablets should weigh 3.25 g.

CT Phenobarbital USP, 30 mg

INGREDIENTS	IN EACH	IN 10,000
Phenobarbital	30.59 mg	305.9 g
Microcrystalline cellulose ^a	30.59 mg	305.9 g
Spray-dried lactose	69.16 mg	691.6 g
Colloidal silica ^b	1.33 mg	13.3 g
Stearic acid	1.33 mg	13.3 g
Weight of granulation		1330 g

^a Avicel-PH-101.

^b QUSO F-22.

Screen the phenobarbital to break up lumps and blend with the microcrystalline cellulose. Add spray-dried lactose and blend. Finally, add the stearic acid and colloidal silica; blend to obtain a homogeneous mixture. Compress, using a $\frac{3}{16}$ -inch, shallow, concave punch. Ten tablets should weigh 1.33 g (courtesy, *FMC*).

Molded Tablets or Tablet Triturates (TT)

Tablet triturates are small, disoid masses of molded powders weighing 30 to 250 mg each. The base consists of lactose, β -lactose, mannitol, dextrose, or other rapidly soluble materials. It is desirable in making tablet triturates to prepare a solid dosage form that is rapidly soluble; as a result they are generally softer than compressed tablets.



Figure 45-33. Hand-molding tablet triturates (courtesy, Merck).

This type of dosage form is selected for a number of drugs because of its rapidly dissolving characteristic. Nitroglycerin in many concentrations is prepared in tablet triturate form since the molded tablet rapidly dissolves when administered by placing under the tongue. Potent alkaloids and highly toxic drugs used in small doses are prepared as tablet triturates that can serve as dispensing tablets to be used as the source of the drug in compounding other formulations or solutions. Narcotics in the form of hypodermic tablets originally were made as tablet triturates because they rapidly dissolve in sterile water for injection prior to administration. Today with stable injections of narcotics available, there is no longer any justification for their use in this manner. Although many hypodermic tablets currently are made, they are used primarily for oral administration.

Tablet triturates are made by forcing a moistened blend of the drug and diluent into a mold, extruding the formed mass, which is allowed to dry. This method is essentially the same as it was when introduced by Fuller in 1878. Hand molds may vary in size, but the method of operation is essentially the same. Molds consist of two plates made from polystyrene plastic, hard rubber, nickel-plated brass, or stainless steel. The mold plate contains 50 to 500 carefully polished perforations. The other plate is fitted with a corresponding number of projecting pegs or punches that fit the perforations in the mold plate. The mold plate is placed on a flat surface, the moistened mass is forced into the perforations, and the excess is scraped from the top surface. The mold plate is placed over the plate with the corresponding pegs and lowered. As the plates come together, the pegs force the tablet triturates from the molds. They remain on the tops of the pegs until dry, and they can be handled (see Fig 45-33). In some hand molds, as shown in Figure 45-34, the pegs are forced down onto the plate holding the moist trituration.




Figure 45-34. Tablet triturate mold (courtesy, Vector/Colton).

FORMULATION

In developing a formula it is essential to know the blank weight of the mold that is to be used. To determine this, the weight of the diluent that exactly fills all the openings in the mold is determined by experiment. This amount of diluent is weighed and placed aside. The total amount of the drug required is determined by multiplying the number of perforations in the plate used in the previous experiment by the amount of drug desired in each tablet. The comparative bulk of this medication is compared with that of an equal volume of diluent and that quantity of diluent is removed and weighed. The drug and the remaining diluent are mixed by trituration, and the resulting triturate is moistened and forced into the openings of the mold. If the perforations are not filled completely, more diluent is added, its weight noted, and the formula written from the results of the experiments.

It is also permissible in the development of the formula to weigh the quantity of medication needed for the number of tablets represented by the number of perforations in the mold, triturate with a weighed portion (more than 1/2) of the diluent, moisten the mixture, and press it into the perforations of the mold. An additional quantity of the diluent is moistened immediately and also forced into the perforations in the plate until they are filled completely. All excess diluent is removed, the trial tablets are forced from the mold, then triturated until uniform, moistened again, if necessary, and remolded. When these tablets are dried thoroughly and weighed, the difference between their total weight and the weight of medication taken will indicate the amount of diluent required and accordingly supply the formula for future use for that particular tablet triturate.

PREPARATION

The mixed powders are moistened with a proper mixture of alcohol and water, although other solvents or moistening agents such as acetone, petroleum benzin, and various combinations of these may be used in specific cases; the agent of choice depends on the solvent action that it will exert on the powder mixture. Often the moistening agent is 50% alcohol, but this concentration may be increased or decreased depending on the constituents of the formula. Care must be used in adding the solvent mixture to the powder. If too much is used, the mass will be soggy and will require a long time to dry, and the finished tablet will be hard and slowly soluble; if the mass is too wet, shrinkage will occur in the molded tablets; finally, a condition known as creeping will be noticed. Creeping is the concentration of the medication on the surface of the tablet caused by capillarity and rapid evaporation of the solvent from the surface. Because molded tablets by their very nature are quite friable, an inaccurate strength in each tablet may result from creeping if powder is lost from the tablet's surface. On the other hand, if an insufficient amount of moistening agent is used, the mass will not have the proper cohesion to make a firm tablet. The correct amount of moistening agent can be determined initially only by experiment.

HAND-MOLDING TABLET TRITURATES

In preparing hand-molded tablets place the mold plate on a glass plate. The properly moistened material is pressed into the perforations of the mold with a broad spatula, exerting uniform pressure over each opening. The excess material is removed by passing the spatula at an oblique angle, with strong hand pressure, over the mold to give a clean, flat surface. The material thus removed should be placed with the remainder of the unmolded material.

The mold with the filled perforations should be reversed and moved to another clean part of the plate where the pressing operation with the spatula is repeated. It may be necessary to add

more material to fill the perforations completely and uniformly. The mold should be allowed to stand in a position so that part of the moistening agent will evaporate equally from both faces. While the first plate is drying, another mold can be prepared. As soon as the second mold has been completed, the first mold should be sufficiently surface-dried so that the pegs will press the tablets from the mold with a minimum of sticking.

To remove the tablets from the mold, place the mold over the peg plate so that the pegs and the perforations are in juxtaposition. The tablets are released from the mold by hand pressure, which forces the pegs through the perforations. The ejected tablets are spread evenly in single layers on silk trays and dried in a clean, dust-free chamber with warm, circulating air. If only a small quantity of tablet triturates is made and no warm-air oven is available, the tablet triturates may be dried to constant weight at room temperature.

MACHINE-MOLDING TABLET TRITURATES

Tablet triturates also can be made using mechanical equipment. The automatic tablet triturate machine illustrated in Figure 45-35 makes tablet triturates at a rate of 2500/min. For machine-molding, the powder mass need not be as moist as for plate-molding, since the time interval between forming the tablets and pressing them is considerably shorter. The moistened mass passes through the funnel of the hopper to the feed plates below. In this feed plate are four holes having the same diameter as the mouth of the funnel. The material fills one hole at a time and, when filled, revolves to a position just over the mold plate. When in position the weighted pressure foot lowers and imprisons the powder. At the same time a spreader in the sole of the pressure foot rubs it into the mold cavities and evens it off so that the triturates are smooth on the surface and are of uniform density. When this operation is completed, the mold passes to the next position, where it registers with a nest of punches or pegs that eject the tablets from the mold plate onto a conveyor belt. The conveyor belt sometimes is extended to a length of 8 or 10 ft. under a battery of infrared drying lamps to hasten the setting of the tablets for more rapid handling. This method of drying can be used only if the drug is chemically stable to these drying conditions.




Figure 45-35. Automatic tablet triturate machine (courtesy, Vector-Colton).

COMPRESSED TABLET TRITURATES

Frequently, tablet triturates are prepared on compression tablet machines using flat-face punches. When solubility and a clear solution are required, water-soluble lubricants must be used to prevent sticking to the punches. The granulations are prepared as directed for ordinary compressed tablets; lactose generally is used as the diluent. Generally, tablet triturates prepared by this method are not as satisfactory as the molded type regarding their solubility and solution characteristics.

TABLET CHARACTERISTICS

Compressed tablets may be characterized or described by a number of specifications. These include the diameter size, shape, thickness, weight, hardness, disintegration time, and dissolution characteristics. The diameter and shape depend on the die and the punches selected for the compression of the tablet. Generally, tablets are discoid in shape, although they may be oval, oblong, round, cylindrical, or triangular. Their upper and lower surfaces may be flat, round, concave, or convex to various degrees. The concave punches (used to prepare convex tablets) are referred to as shallow, standard, and deep cup, depending on the degree of concavity (see Figs 45-17 to 45-20). The tablets may be scored in halves or quadrants to facilitate breaking if a smaller dose is desired. The top or lower surface may be embossed or engraved with a symbol or letters that serve as an additional means of identifying the source of the tablets. These characteristics along with the color of the tablets tend to make them distinctive and identifiable with the active ingredient that they contain.

The remaining specifications assure the manufacturer that the tablets do not vary from one production lot to another. In the case of new tablet formulations their therapeutic efficacy is demonstrated through clinical trials, and it is the manufacturer's aim to reproduce the same tablet with the exact characteristics of the tablets that were used in the clinical evaluation of the dosage form. Therefore, from the control viewpoint these specifications are important for reasons other than physical appearance.

Tablet Hardness

The resistance of the tablet to chipping, abrasion, or breakage under conditions of storage, transportation, and handling before usage depends on its hardness. In the past, a rule of thumb described a tablet to be of proper hardness if it was firm enough to break with a sharp snap when it was held between the 2nd and 3rd fingers and using the thumb as the fulcrum, yet didn't break when it fell on the floor. For obvious reasons and control purposes a number of attempts have been made to quantitate the degree of hardness.

A small and portable hardness tester was manufactured and introduced in the mid-1930s by *Monsanto*. It now is distributed by the Stokes Div (*Pennwalt*) and may be designated as either the Monsanto or Stokes hardness tester. The instrument measures the force required to break the tablet when the force generated by a coil spring is applied diametrically to the tablet. The force is measured in kilograms and when used in production, a hardness of 4 kg is considered to be minimum for a satisfactory tablet.

The Strong-Cobb hardness tester introduced in 1950 also measures the diametrically applied force required to break the tablet. In this instrument the force is produced by a manually operated air pump. As the pressure is increased, a plunger is forced against the tablet placed on anvil. The final breaking point is indicated on a dial calibrated into 30 arbitrary units. The hardness values of the Stokes and Strong-Cobb instruments are not equivalent. Values obtained with the Strong-Cobb tester have been found to be 1.6 times those of the Stokes tester.

Another instrument is the Pfizer hardness tester, which operates on the same mechanical principle as ordinary pliers. The force required to break the tablet is recorded on a dial and may be expressed in either kilograms or pounds of force. In an experimental comparison of testers the Pfizer and the Stokes testers were found to check each other fairly well. Again the Strong-Cobb tester was found to give values 1.4 to 1.7 times the absolute values on the other instruments.

The most widely used apparatus to measure tablet hardness or crushing strength is the Schleuniger apparatus, also known as the Heberlein, distributed by *Vector*. This and other, newer, electrically operated test equipment eliminate the operator variability inherent in the measurements described above. Newer equipment is also available with printers to provide a record of test results. See Figure 45-36.

Manufacturers, such as *Key*, *Van Kel*, *Erweka*, and others, make similar hardness testers.

Hardness (or more appropriately, crushing strength) determinations are made throughout the tablet runs to determine the need for pressure adjustments on the tableting machine. If the tablet is too hard, it may not disintegrate in the required period of time or meet the dissolution specification; if it is too soft, it will not withstand the handling during subsequent processing such as coating or packaging and shipping operations.

A tablet property related to hardness is *friability*, and the measurement is made by use of the Roche friabilator. Rather than a measure of the force required to crush a tablet, the instrument is designed to evaluate the ability of the tablet to withstand abrasion in packaging, handling, and shipping. A number of tablets are weighed and placed in the tumbling apparatus where they are exposed to rolling and repeated shocks resulting from freefalls within the apparatus. After a given number of rotations the tablets are weighed, and the loss in weight indicates the ability of the tablets to withstand this type of wear (Fig 45-37).

Recent research has proposed that there are at least three measurable hardness parameters that can give a clue to the compatibility and intrinsic strength of powdered materials. These include bonding strength, internal strain, and brittleness. Hiestand proposed indices to quantify these parameters, and they are listed in Table 45-4 for a number of materials.

The higher the bonding index, the stronger a tablet is likely to be. The higher the strain index, the weaker the tablet. Since the two parameters are opposite in their effect on the tablet, it is possible for a material (such as Avicel) to have a relatively high strain index, but yet have superior compaction properties because of an extraordinary bonding potential. The higher the brittleness index, the more friable the tablet is likely to be. For




Figure 45-36. The Schleuniger or Heberlein tablet hardness tester shown with calibration blocks (courtesy, Vector).




Figure 45-37. The Roche friabilator (courtesy, Hoffmann-LaRoche).

a more detailed discussion of this subject, the reader is directed to References 22, 37, 38.

A similar approach is taken by many manufacturers when they evaluate a new product in the new market package by sending the package to distant points and back using various methods of transportation. This is called a *shipping test*. The condition of the product on its return indicates its ability to withstand transportation handling.

Tablet Thickness

The thickness of the tablet from production-run to production-run is controlled carefully. Thickness can vary with no change in weight because of difference in the density of the granulation and the pressure applied to the tablets, as well as the speed of tablet compression. Not only is the tablet thickness important in reproducing tablets identical in appearance but also to ensure that every production lot will be usable with selected packaging components. If the tablets are thicker than specified, a given number no longer may be contained in the volume of a given size bottle. Tablet thickness also becomes an important characteristic in counting tablets using filling equipment. Some filling equipment uses the uniform thickness of the tablets as a counting mechanism. A column containing a known number of tablets is measured for height; filling is accomplished by continually dropping columns of tablets of the same height into bottles. If thickness varies throughout the lot, the result will be variation in count. Other pieces of filling equipment can malfunction because of variation in tablet thickness, since tablets above specified thickness may cause wedging of tablets in previously adjusted depths of the counting slots. Tablet thickness is determined with a caliper or thickness gauge that measures the thickness in millimeters. Plus or minus 5% may be allowed, depending on the size of the tablet.

Table 45-4. Hiestand Compaction Indices for a Number of Materials

MATERIAL	BONDING INDEX	STRAIN INDEX	BRITTLINESS INDEX
Aspirin	1.5	1.11	0.16
Dicalcium phosphate	1.3	1.13	0.15
Lactose anhydrous	0.8	1.40	0.27
Avicel pH 102	4.3	2.20	0.04
Corn starch	0.4	2.48	0.26
Sucrose NF	1.0	1.45	0.35
Erythromycin dihydrate	1.9	2.13	0.98

Uniformity of Dosage Forms

TABLET WEIGHT—The volumetric fill of the die cavity determines the weight of the compressed tablet. In setting up the tablet machine the fill is adjusted to give the desired tablet weight. The weight of the tablet is the quantity of the granulation that contains the labeled amount of the therapeutic ingredient. After the tablet machine is in operation the weights of the tablets are checked routinely, either manually or electronically, to ensure that proper-weight tablets are being made. This has become rather routine in most manufacturing operations with newer, electronically controlled tablet presses. The USP has provided tolerances for the average weight of uncoated compressed tablets. These are applicable when the tablet contains 50 mg or more of the drug substance or when the latter comprises 50% or more, by weight, of the dosage form. Twenty tablets are weighed individually, and the average weight is calculated. The variation from the average weight in the weights of not more than two of the tablets must not differ by more than the percentage listed below; no tablet differs by more than double that percentage. Tablets that are coated are exempt from these requirements but must conform to the test for content uniformity if it is applicable.

AVERAGE WEIGHT	PERCENT DIFFERENCE
130 mg or less	10
More than 130 mg through 324 mg	7.5
More than 324 mg	5

CONTENT UNIFORMITY—To ensure that every tablet contains the amount of drug substance intended, with little variation among tablets within a batch, the USP includes the content uniformity test for certain tablets. Due to the increased awareness of physiological availability, the content uniformity test has been extended to monographs on all coated and uncoated tablets and all capsules intended for oral administration where the range of sizes of the dosage form available includes a 50 mg or smaller size, in which case the test is applicable to all sizes (50 mg and larger and smaller) of that tablet or capsule. The official compendia can be consulted for the details of the test. Tablet monographs with a content uniformity requirement do not have a weight variation requirement.

Tablet Disintegration

It is recognized generally that the *in vitro* tablet disintegration test does not necessarily bear a relationship to the *in vivo* action of a solid dosage form. To be absorbed, a drug substance must be in solution, and the disintegration test is a measure only of the time required under a given set of conditions for a group of tablets to disintegrate into particles. Generally, this test is useful as a quality-assurance tool for conventional (non-sustained-release) dosage forms. In the present disintegration test the particles are those that will pass through a 10-mesh screen. In a comparison of disintegration times and dissolution rates or initial absorption rates of several brands of aspirin tablets, it was found that the faster-absorbed tablets had the longer disintegration time. Regardless of the lack of significance as to *in vivo* action of the tablets, the test provides a means of control in ensuring that a given tablet formula is the same as regards disintegration from one production batch to another. The disintegration test is used as a control for tablets intended to be administered by mouth, except for tablets intended to be chewed before being swallowed or tablets designed to release the drug substance over a period of time.

Exact specifications are given for the test apparatus, inasmuch as a change in the apparatus can cause a change in the results of the test. The apparatus consists of a basket rack holding six plastic tubes, open at the top and bottom; the bottom of the tubes is covered with 10-mesh screen. See Figure 45-38. The basket rack is immersed in a bath of suitable liquid, held at 37°C,




Figure 45-38. Vanderkamp tablet disintegration tester (courtesy, VanKel).

preferably in a 1-L beaker. The rack moves up and down in the fluid at a specified rate. The volume of the fluid is such that on the upward stroke the wire mesh remains at least 2.5 cm below the surface of the fluid and descends to not less than 2.5 cm from the bottom on the downward stroke. Tablets are placed in each of the six cylinders along with a plastic disc over the tablet unless otherwise directed in the monograph. The endpoint of the test is indicated when any residue remaining is a soft mass with no palpably soft core. The plastic discs help to force any soft mass that forms through the screen.

For compressed, uncoated tablets the testing fluid is usually water at 37°, but in some cases the monographs direct that Simulated Gastric Fluid TS be used. If one or two tablets fail to disintegrate, the test is to be repeated using 12 tablets. Of the 18 tablets then tested, 16 must have disintegrated within the given period of time. The conditions of the test are varied somewhat for coated tablets, buccal tablets, and sublingual tablets. Disintegration times are included in the individual tablet monograph. For most uncoated tablets the period is 30 min, although the time for some uncoated tablets varies greatly from this. For coated tablets up to 2 hr may be required, while for

sublingual tablets, such as CT Isoproterenol Hydrochloride, the disintegration time is 3 min. For the exact conditions of the test, consult the USP.

Dissolution Test

For certain tablets the monographs direct compliance with limits on dissolution rather than disintegration. Since drug absorption and physiological availability depend on having the drug substance in the dissolved state, suitable dissolution characteristics are an important property of a satisfactory tablet. Like the disintegration test, the dissolution test for measuring the amount of time required for a given percentage of the drug substance in a tablet to go into solution under a specified set of conditions is an *in vitro* test. It is intended to provide a step toward the evaluation of the physiological availability of the drug substance, but as described currently, it is not designed to measure the safety or efficacy of the tablet being tested. Both the safety and effectiveness of a specific dosage form must be demonstrated initially by means of appropriate *in vivo* studies and clinical evaluation. Like the disintegration test, the dissolution test does provide a means of control in ensuring that a given tablet formulation is the same as regards dissolution as the batch of tablets shown initially to be clinically effective. It also provides an *in vitro* control procedure to eliminate variations among production batches. Refer to Chapter 35 for a complete discussion of dissolution testing.

Validation

In this era of increasing regulatory control of the pharmaceutical industry, manufacturing procedures cannot be discussed without the mention of some process-validation activity. By way of documentation, product testing, and perhaps in-process testing as well, manufacturers can demonstrate that their formulas and processes perform in the manner expected and that they do so reproducibly.

Although the justification for requiring validation is found in the regulations relating to *Current Good Manufacturing Practices for Finished Pharmaceuticals* as well as other sources, there is still much room for interpretation, and the process varies from one company to another. General areas of agreement appear to be that

The validation activity must begin in R&D and continue through product introduction.

Documentation is the key.

In general, three batches represent an adequate sample for validation.

The FDA has rejected historical data or *retrospective validation*. They require that new products be validated from beginning to end, a process called *prospective validation*.

CAPSULES

Capsules are solid dosage forms in which the drug substance is enclosed in either a hard or soft, soluble container or shell of a suitable form of gelatin. The soft gelatin capsule was invented by Mothes, a French pharmacist, in 1833. During the following year DuBlanc obtained a patent for his soft gelatin capsules. In 1848 Murdock patented the two-piece hard gelatin capsule. Although development work has been done on the preparation of capsules from methylcellulose, starch and calcium alginate, gelatin, because of its unique properties, remains the primary composition material for the manufacture of capsules. The gelatin used in the manufacture of capsules is obtained from collagenous material by hydrolysis. There are two types of gelatin, Type A, derived mainly from pork skins by acid processing, and Type B, obtained from bones and animal skins by

alkaline processing. Blends are used to obtain gelatin solutions with the viscosity and bloom strength characteristics desirable for capsule manufacture.⁵⁰

The encapsulation of medicinal agents remains a popular method for administering drugs. Capsules are tasteless, easily administered, and easily filled either extemporaneously or in large quantities commercially. In prescription practice the use of hard gelatin capsules permits a choice in prescribing a single drug or a combination of drugs at the exact dosage level considered best for the individual patient. This flexibility is an advantage over tablets. Some patients find it easier to swallow capsules than tablets, therefore preferring to take this form when possible. This preference has prompted pharmaceutical manufacturers to market the product in capsule

form, even though the product already has been produced in tablet form. While the industry prepares approximately 75% of its solid dosage forms as compressed tablets, 23% as hard gelatin capsules, and 2% as soft elastic capsules, market surveys have indicated a consumer preference of 44.2% for soft elastic capsules, 39.6% for tablets, and 19.4% for hard gelatin capsules.⁵¹

HARD GELATIN CAPSULES

The hard gelatin capsule, also referred to as the dry-filled capsule (DFC), consists of two sections, one slipping over the other, thus completely surrounding the drug formulation. The classic capsule shape is illustrated in Figure 45-39. These capsules are filled by introducing the powdered material into the longer end or body of the capsule and then slipping on the cap. Hard gelatin capsules are made largely from gelatin, FD&C colorants, and sometimes an opacifying agent such as titanium dioxide; the USP permits the gelatin for this purpose to contain 0.15% sulfur dioxide to prevent decomposition during manufacture. Hard gelatin capsules contain 12–16% water, but the water content can vary depending on the storage conditions. When the humidity is low, the capsules become brittle; if stored at high humidities, the capsules become flaccid and lose their shape. Storage in high-temperature areas also can affect the quality of hard gelatin capsules. Gelatin capsules do not protect hygroscopic materials from atmospheric water vapor, as moisture can diffuse through the gelatin wall.

Companies having equipment for preparing empty hard gelatin capsules include *Lilly*, *Parke-Davis*, *Scherer*, and *SmithKline*. The latter's production is mainly for its own use; the others are suppliers to the industry. With this equipment, stainless steel pins, set in plates, are dipped into the gelatin solution, which must be maintained at a uniform temperature and an exact degree of fluidity. If the gelatin solution varies in viscosity, it correspondingly will decrease or increase the thickness of the capsule wall. This is important since a slight variation is sufficient to make either a loose or a tight joint. When the pins have been withdrawn from the gelatin solution, they are rotated while being dried in kilns through which a strong blast of filtered air with controlled humidity is forced. Each capsule is stripped, trimmed to uniform length and joined, the entire process being mechanical. Capsule-making equipment is illustrated in Figures 45-40 and 45-41. These show the stainless steel pins being dipped into the gelatin solutions and then being rotated through the drying kiln.

Capsules are supplied in a variety of sizes. The hard, empty capsules (Fig 45-39) are numbered from 000, the largest size that can be swallowed, to 5, which is the smallest. Larger sizes are available for use in veterinary medicine. The approximate capacity for capsules from 000 to 5 ranges from 600 to 30 mg, although this will vary because of the different densities of powdered drug materials.

Commercially filled capsules have the conventional oblong shape illustrated, with the exception of capsule products by *Lilly* and *SmithKline*, which are of distinctive shape. For Lilly




Figure 45-39. Hard gelatin capsules showing relative sizes (courtesy, Parke-Davis).




Figure 45-40. Manufacture of hard gelatin capsules by dipping stainless steel pins into gelatin solutions (courtesy, Lilly).

products, capsules are used in which the end of the base is tapered to give the capsule a bullet-like shape; products encapsulated in this form are called *Pulvules*. The *SmithKline* capsules differ in that both ends of the cap and body are angular, rather than round.

After hard gelatin capsules are filled and the cap applied, there are a number of methods used to ensure that the capsules will not come apart if subjected to vibration or rough handling, as in high-speed counting and packaging equipment. The capsules can be spot-welded by means of a heated metal pin pressed against the cap, fusing it to the body, or they may be banded with molten gelatin laid around the joint in a strip and dried. Colored gelatin bands around capsules have been used for many years as a trademark by *Parke-Davis* for their line of capsule products, *Kapseals*. Another approach was used in the *Snap-Fit* and *Coni-Snap* capsules. A pair of matched locking rings are formed into the cap and body portions of the capsule. Prior to filling, these capsules are slightly longer than regular capsules of the same size. When the locking rings are engaged after filling, their length is equivalent to that of the conventional capsule.

Following several tampering incidents, many pharmaceutical companies now use any number of locking and sealing technologies to manufacture and distribute these very useful dosage forms safely. Unfortunately, tamper-resistant packaging has become standard for capsule products.




Figure 45-41. Formed capsules being dried by rotating through a drying kiln (courtesy, Lilly).




Figure 45-42. Hand-operated capsule machine (courtesy, Chemi-Pharm).

It is usually necessary for the pharmacist to determine the size of the capsule needed for a given prescription through experimentation. The experienced pharmacist, having calculated the weight of material to be held by a single capsule, often will select the correct size immediately. If the material is powdered, the base of the capsule is filled and the top is replaced. If the material in the capsule proves to be too heavy after weighing, a smaller size must be taken and the test repeated. If the filled capsule is light, it is possible that more can be forced into it by increasing the pressure or, if necessary, some of the material may be placed in the cap. This is not desirable as it tends to decrease the accuracy of subdivision and it is much better to select another size, whose base will hold exactly the correct quantity. In prescription filling it is wise to check the weight of each filled capsule.

In addition to the transparent, colorless, hard gelatin capsule, capsules are also available in various transparent colors such as pink, green, reddish brown, blue, yellow, and black. If they are used, it is important to note the color as well as the capsule size on the prescription so that in the case of renewal the refilled prescription will duplicate the original. Colored capsules have been used chiefly by manufacturers to give a specialty product a distinctive appearance. Titanium dioxide is added to the gelatin to form white capsules or to make an opaque, colored capsule. In addition to color contrasts, many commercial products in capsules are given further identification by markings, which may be the company's name, a symbol on the outer shell of the capsule, or banding. Some manufacturers mark capsules with special numbers based on a coded system to permit exact identification by the pharmacist or physician.

Extemporaneous Filling Methods

When filling capsules on prescription, the usual procedure is to mix the ingredients by trituration, reducing them to a fine and uniform powder. The principles and methods for the uniform distribution of an active medicinal agent in a powder mixture are discussed in Chapter 37. Granular powders do not pack readily in capsules, and crystalline materials, especially those that consist of a mass of filament-like crystals such as the quinine salts, are not fitted easily into capsules unless powdered. Eutectic mixtures that tend to liquefy may be dispensed in capsules if a suitable absorbent such as magnesium carbonate is used. Potent drugs given in small doses usually are mixed with an inert diluent such as lactose before filling into capsules. When incompatible materials are prescribed together, it is sometimes possible to place one in a smaller capsule and then enclose it with the second drug in a larger capsule.

Usually, the powder is placed on paper and flattened with a spatula so that the layer of powder is not greater than about $\frac{1}{8}$ the length of the capsule that is being filled. This helps to keep both the hands and capsules clean. The cap is removed from the selected capsule and held in the left hand; the body is pressed repeatedly into the powder until it is filled. The cap is replaced and the capsule is weighed. In filling the capsule the spatula is helpful in pushing the last quantity of the material into the capsule. If each capsule has not been weighed, there is likely to be an excess or a shortage of material when the specified number of capsules have been packed. This condition is adjusted before dispensing the prescription.

A number of manual filling machines and automatic capsule machines are available for increasing the speed of the capsule-filling operation. Figure 45-42 illustrates a capsule-filling machine that was known formerly as the Sharp & Dohme machine. This equipment is now available through ChemiPharm. Many community pharmacists find this a useful piece of apparatus, and some pharmaceutical manufacturers use it for small-scale production of specialty items. The machine fills 24 capsules at a time with the possible production of 2000 per day. Entire capsules are placed in the machine by hand; the lower plate carries a clamp that holds the capsule bases and makes it possible to remove and replace the caps mechanically. The plate holding the capsule bases is perforated for three sizes of capsules. The powder is packed in the bases; the degree of accuracy depends on the selection of capsule size and the amount of pressure applied in packing. The hand-operated machine (Model 300, ChemiPharm) illustrated in Figure 45-43 has a production capacity of 2000 capsules per hour. The machine is made for a single capsule size and cannot be changed over for other sizes. A different machine is required for any additional capsule size. Its principle of operation is similar to that of the Sharp & Dohme machine.

Machine Filling Methods

Large-scale filling equipment for capsules operates on the same principle as the manual machines described above, namely the filling of the base of the capsule. Compared with tablets,




Figure 45-43. Hand-operated capsule machine, Model 300 (courtesy, ChemiPharm).

Table 45-5. Capsule Fill Chart

CAPSULE FILL WEIGHTS (MG) BASED ON SIZE AND DENSITY

POWDER DENSITY (g/ml)	CAPSULE VOLUME (mL)									
	0.95	0.78	0.68	0.54	0.5	0.37	0.3	0.25	0.21	0.13
	CAPSULE SIZE									
	00	0el	0	1el	1	2	3	4el	4	5
0.3	285	234	204	162	150	111	90	75	63	39
0.4	380	312	272	216	200	148	120	100	84	52
0.5	475	390	340	270	250	185	150	125	105	65
0.6	570	468	408	324	300	222	180	150	126	78
0.7	665	546	476	378	350	259	210	175	147	91
0.8	760	624	544	432	400	296	240	200	168	104
0.9	855	702	612	486	450	333	270	225	189	117
1.0	950	780	680	540	500	370	300	250	210	130
1.1	1045	858	748	594	550	407	330	275	231	143
1.2	1140	936	816	648	600	444	360	300	252	156
1.3	1235	1014	884	702	650	481	390	325	273	169
1.4	1330	1092	952	756	700	518	420	350	294	182
1.5	1425	1170	1020	810	750	555	450	375	315	195

powders for filling into hard gelatin capsules require a minimum of formulation efforts. The powders usually contain diluents such as lactose, mannitol, calcium carbonate, or magnesium carbonate. Since the flow of material is of great importance in the rapid and accurate filling of the capsule bodies, lubricants such as the stearates also are used frequently.

Because of the absence of numerous additives and manufacturing processing, the capsule form is used frequently to administer new drug substances for evaluation in initial clinical trials. However, it is now realized that the additives present in the capsule formulation, like the compressed tablet, can influence the release of the drug substance from the capsule. Tablets and capsules of a combination product containing triamterene and hydrochlorothiazide in a 2:1 ratio were compared clinically. The tablet caused approximately twice as much excretion of hydrochlorothiazide and three times as much triamterene as the capsule.⁵²

Most equipment operates on the principle by which the base of the capsule is filled and the excess is scraped off. Therefore, the active ingredient is mixed with sufficient volume of a diluent, usually lactose or mannitol, to give the desired amount of the drug in the capsule when the base is filled with the powder mixture. The manner of operation of the machine can influence the volume of powder that will be filled into the base of the capsule; therefore, the weights of the capsules must be checked routinely as they are filled. See Table 45-5.

Semiautomatic capsule-filling machines manufactured by *Parke-Davis* and *Lilly* are illustrated in Figures 45-44 and 45-45. The Type 8 capsule-filling machine performs mechanically under the same principle as the hand filling of capsules. This includes separation of the cap from the body, filling the body half, and rejoining the cap and body halves.

Empty capsules are taken from the bottom of the capsule hopper into the magazine. The magazine gauge releases one




Figure 45-44. Schematic of Type 8 capsule-filling machine (courtesy, Parke-Davis).




Figure 45-45. Type 8 capsule-filling machine (courtesy, Lilly).

capsule from each tube at the bottom of each stroke of the machine. Leaving the magazine, the capsules drop onto the tracks of the raceway and are pushed forward to the rectifying area with a push blade. The rectifier block descends, turning the capsules in each track, cap up, and drops them into each row of holes in the capsule-holding ring assembly.

As the capsules fall into the holding ring, the cap half has a seat on the counter bore in each hole for the top ring. The body half is pulled by vacuum down into the bottom ring. When all rows in the ring assembly are full, the top ring, filled with caps only, is removed and set aside for later assembly. The body halves now are located in the bottom ring, ready for filling.

The ring holding the body halves is rotated at one of eight speeds on the rotary table. The drug hopper is swung over the rotating ring, and the auger forces drug powder into the open body cavities. When the ring has made a complete revolution and the body halves have been filled, the hopper is swung aside. The cap-holding ring is placed over the body-holding ring and the assembly is ready for joining. The capsule-holding ring assembly is placed on the joiner and the joiner plate is swung down into position to hold the capsules in the ring. The peg ring pins are entered in the holes of the body holding ring and tapped in place by the air cylinder pushing the body halves back into the cap halves.

The holding-ring assembly is now pushed by hand back onto the peg ring away from the joiner plate, thus pushing the capsules out of the holding-ring assembly. The joined capsules then fall through the joiner chute into the capsule receiver box. The capsule receiver box screens the excess powder from the capsules and delivers them to any convenient container.

Many companies use the Type 8 capsule-filling equipment for small-scale manufacture and clinical supplies for investigational use because of its ease of operation, low cost, and extreme flexibility. A Type 8 capsule filling machine will produce approximately 200,000 capsules per day. This, of course, depends upon the operator and the type of material being filled. For this machine, a mathematical model has been developed that describes the effect of selected physical powder properties as well as mechanical operating conditions on the capsule-filling operation. While the Type 8 capsule-filling machine has been in existence for many years, recent modifications have been made to this machine to improve the capsule-filling operations.

There are several pieces of equipment available that are classified as automatic capsule-filling machines. These are automatic in the sense that one operator can handle more than one machine. In this category are the Italian-made Zanasi (*United Machinery*) and MG-2 (*Supermatic*) models, plus the West German-made Hoeffliger & Karg models (*Bosch*).

Automatic capsule machines are capable of filling either powder or granulated products into hard gelatin capsules. With accessory equipment these machines also can fill pellets or place a tablet into the capsule with the powder or pellets. The capsules are fed at random into a large hopper. They are oriented as required and transferred into holders where the two halves are separated by suction. The top-half and bottom-half of the capsules are in separate holders, which at this stage take diverting directions.

A set of filling heads collects the product from the hopper, compresses it into a soft slug, and inserts this into the bottom half of the capsule. After filling, each top-half is returned to the corresponding bottom-half. The filled capsules are ejected, and an air blast at this point separates possible empty capsules from the filled. The machines can be equipped to handle all sizes of capsules. Depending upon the make and model, speeds from 9000 to 150,000 units per hour can be obtained (see Figs 45-46 to 45-48).

All capsules, whether they have been filled by hand or by machine, will require cleaning. Small quantities of capsules may be wiped individually with cloth. Larger quantities are rotated or shaken with crystalline sodium chloride. The capsules then are rolled on a cloth-covered surface.




Figure 45-46. MG-2, automatic capsule-filling machine (courtesy, Supermatic).

Uniformity of Dosage Units

The uniformity of dosage forms can be demonstrated by either of two methods, weight variation or content uniformity. Weight variation may be applied when the product is a liquid-filled, soft, elastic capsule or when the hard gelatin capsule contains 50 mg or more of a single active ingredient comprising 50% or more, by weight, of the dosage form. See the official compendia for details.

Disintegration tests usually are not required for capsules unless they have been treated to resist solution in gastric fluid (enteric-coated). In this case they must meet the requirements for disintegration of enteric-coated tablets. For certain capsule dosage forms a dissolution requirement is part of the monograph. Procedures used are similar to those employed in the case of compressed tablets.




Figure 45-47. Zanasi automatic filling machine, Model AZ-60. The set of filling heads shown at the left collects the powder from the hopper, compresses it into a soft slug, and inserts it into the bottom half of the capsule (courtesy, United Machinery).




Figure 45-48. Hoefliger & Karg automatic capsule-filling machine, Model GFK 1200 (courtesy, Amaco).

SOFT ELASTIC CAPSULES

The soft elastic capsule (SEC) is a soft, globular, gelatin shell somewhat thicker than that of hard gelatin capsules. The gelatin is plasticized by the addition of glycerin, sorbitol, or a similar polyol. The soft gelatin shells may contain a preservative to prevent the growth of fungi. Commonly used preservatives are methyl- and propylparabens and sorbic acid. When the suspending vehicle or solvent can be an oil, soft gelatin capsules provide a convenient and highly acceptable dosage form. Large-scale production methods generally are required for the preparation and filling of soft gelatin capsules.

Formerly, empty soft gelatin capsules were available to the pharmacist for the extemporaneous compounding of solutions or suspensions in oils. Commercially filled soft gelatin capsules come in a wide choice of sizes and shapes; they may be round, oval, oblong, tubular, or suppository-shaped. Some sugar-coated tablets are quite similar in appearance to soft

gelatin capsules. The essential differences are that the soft gelatin capsule has a seam at the point of closure of the two halves, and the contents can be liquid, paste, or powder. The sugar-coated tablet will not have a seam but will have a compressed core.

Oral SEC dosage forms generally are made so that the heat seam of the gelatin shell opens to release its liquid medication into the stomach less than 5 min after ingestion. Its use is being studied for those drugs poorly soluble in water having bioavailability problems. When used as suppositories, it is the moisture present in the body cavity that causes the capsule to come apart at its heat-sealed seam and to release its contents.

Plate Process

In this method a set of molds is used. A warm sheet of prepared gelatin is laid over the lower plate, and the liquid is poured on it. A second sheet of gelatin is carefully put in place, and this is followed by the top plate of the mold. The set is placed under the press where pressure is applied to form the capsules, which are washed off with a volatile solvent to remove any traces of oil from the exterior. This process has been adapted and is used for encapsulation by *Upjohn*. The sheets of gelatin may have the same color or different colors.

Rotary-Die Process

In 1933 the rotary-die process for elastic capsules was perfected by Robert P Scherer.⁵³ This process made it possible to improve the standards of accuracy and uniformity of elastic gelatin capsules and globules.

The rotary-die machine is a self-contained unit capable of continuously and automatically producing finished capsules from a supply of gelatin mass and filling material, which may be any liquid, semiliquid, or paste that will not dissolve gelatin. Two continuous gelatin ribbons, which the machine forms, are brought into convergence between a pair of revolving dies and an injection wedge. Accurate filling under pressure and sealing of the capsule wall occur as dual and coincident operations; each is delicately timed against the other. Sealing also severs the completed capsule from the net. The principle of operation is shown in Figure 45-49. See also Figure 45-50.




Figure 45-49. Rotary-die elastic capsule filler.




Figure 45-50. Scherer soft elastic capsule machine (courtesy, Scherer).

By this process the content of each capsule is measured individually by a single stroke of a pump so accurately constructed that plunger travel of 0.025 inch will deliver 1 <minim> (apoth). The Scherer machine contains banks of pumps so arranged that many capsules may be formed and filled simultaneously. All pumps are engineered to extremely small mechanical tolerances and to an extremely high degree of precision and similarity. All operations are controlled on a weight basis by actual periodic checks with a group of analytical balances. Individual net-fill weights of capsules resulting from large-scale production vary no more than ± 1 to 3% from theory, depending upon the materials used.

The rotary-die process makes it possible to encapsulate heavy materials such as ointments and pastes. In this manner solids can be milled with a vehicle and filled into capsules. When it is desirable to have a high degree of accuracy and a hermetically sealed product, this form of enclosure is suited ideally.

The modern and well-equipped capsule plant is completely air conditioned, a practical necessity for fine capsule production. Its facilities and operations include the availability of carbon dioxide at every exposed point of operation for the protection of oxidizable substances before encapsulation. Special ingredients also have been used in the capsule shell to exclude light wavelengths that are destructive to certain drugs.

Norton Capsule Machine

This machine produces capsules completely automatically by leading two films of gelatin between a set of vertical dies. These dies as they close, open, and close are in effect a continual vertical plate forming row after row of pockets across the gelatin film. These are filled with medicament and, as they progress through the dies, are sealed, shaped, and cut out of the film as capsules, which drop into a cooled solvent bath.

Accogel Capsule Machine

Another means of soft gelatin encapsulation uses the Accogel machine and process which were developed at *Lederle*. The Accogel, or Stern machine, uses a system of rotary dies but is unique in that it is the only machine that successfully can fill dry powder into a soft gelatin capsule. The machine is available to the entire pharmaceutical industry by a lease arrangement and is used in many countries of the world. It is extremely versatile, not only producing capsules with dry powder but also encapsulating liquids and combinations of liquids and powders. By means of an attachment, slugs or compressed tablets may be enclosed in a gelatin film. The capsules can be made in a variety of colors, shapes, and sizes.

Microencapsulation

As a technology, microencapsulation is placed in the section on capsules only because of the relationship in terminology to mechanical encapsulation described above. The topic is also discussed in Chapter 47 (Extended-release and Targeted Drug Delivery Systems) of this text. Essentially, microencapsulation is a process or technique by which thin coatings can be applied reproducibly to small particles of solids, droplets of liquids, or dispersions, thus forming microcapsules. It can be differentiated readily from other coating methods in the size of the particles involved; these range from several tenths of a micrometer to 5000 μm in size.

A number of microencapsulation processes have been disclosed in the literature.⁵⁴ Some are based on chemical processes and involve a chemical or phase change; others are mechanical and require special equipment to produce the physical change in the systems required.

A number of coating materials have been used successfully; examples of these include gelatin, polyvinyl alcohol, ethylcellu-

lose, cellulose acetate phthalate, and styrene maleic anhydride. The film thickness can be varied considerably, depending on the surface area of the material to be coated and other physical characteristics of the system. The microcapsules may consist of a single particle or clusters of particles. After isolation from the liquid manufacturing vehicle and drying, the material appears as a free-flowing powder. The powder is suitable for formulation as compressed tablets, hard gelatin capsules, suspensions, and other dosage forms.

The process provides answers for problems such as masking the taste of bitter drugs, a means of formulating prolonged-action dosage forms, a means of separating incompatible materials, a method of protecting chemicals against moisture or oxidation, and a means of modifying a material's physical characteristics for ease of handling in formulation and manufacture.

Among the processes applied to pharmaceutical problems is that developed by the National Cash Register Co (NCR). The NCR process is a chemical operation based on phase separation or coacervation techniques. In colloidal chemistry, coacervation refers to the separation of a liquid precipitate, or phase, when solutions of two hydrophilic colloids are mixed under suitable conditions.

The NCR process, using phase separation or coacervation techniques, consists of three steps:

1. Formation of three immiscible phases: a liquid manufacturing phase, a core material phase, and a coating material phase.
2. Deposition of the liquid polymer coating on the core material.
3. Rigidizing the coating, usually by thermal, cross-linking, or desolvation techniques, to form a microcapsule.

In Step 2, the deposition of the liquid polymer around the core material occurs only if the polymer is absorbed at the interface formed between the core material and the liquid vehicle phase. In many cases physical or chemical changes in the coating polymer solution can be induced so that phase separation (coacervation) of the polymer will occur. Droplets of concentrated polymer solution will form and coalesce to yield a two-phase, liquid-liquid system. In cases in which the coating material is an immiscible polymer or insoluble liquid polymer, it may be added directly. Also monomers can be dissolved in the liquid vehicle phase and, subsequently, polymerized at the interface.

Equipment required for microencapsulation by this method is relatively simple; it consists mainly of jacketed tanks with variable-speed agitators. Figure 45-51 shows a typical flow diagram of a production installation.

Other Oral Solid Dosage Forms

PILLS

Pills are small, round, solid, dosage forms containing a medicinal agent and are intended for oral administration. Pills were formerly the most extensively used oral dosage form, but they have been replaced largely by compressed tablets and capsules. Substances that are bitter or unpleasant to the taste, if not corrosive or deliquescent, can be administered in this form if the dose is not too large.

Formerly, pills were made extemporaneously by the community pharmacist whose skill at pill-making became an art. However, the few pills that are now used in pharmacy are prepared on a large scale with mechanical equipment. The pill formulas of the NF were introduced largely for the purpose of establishing standards of strength for the well-known and currently used pills. Hexylresorcinol Pills consist of hexylresorcinol crystals covered with a rupture-resistant coating that is dispersible in the digestive tract. It should be noted that the official hexylresorcinol pills are prepared not by traditional methods but by a patented process, the gelatin coating being sufficiently tough that it cannot be broken readily, even when chewed. Therefore,




Figure 45-51. Production installation for the microencapsulation process (courtesy, NCR).

the general method for the preparation of pills does not apply to hexylresorcinol pills.

Previous editions of this text should be consulted for methods of pill preparation.

TROCHES

These forms of oral medication, also known as *lozenges* or *pastilles*, are discoid-shaped solids containing the medicinal agent in a suitably flavored base. The base may be a hard sugar candy, glycerinated gelatin, or the combination of sugar with sufficient mucilage to give it form. Troches are placed in the mouth, where they slowly dissolve, liberating the active ingredient. The drug involved can be an antiseptic, local anesthetic, antibiotic, antihistaminic, antitussive, analgesic, or a decongestant.

Formerly, troches were prepared extemporaneously by the pharmacist. The mass is formed by adding water slowly to a mixture of the powdered drug, powdered sugar, and a gum until a pliable mass is formed. Powdered acacia in 7% concentration gives sufficient adhesiveness to the mass. The mass is rolled out and the troche pieces cut out using a cutter, or else the mass is rolled into a cylinder and divided. Each piece is shaped and allowed to dry before dispensing.

If the active ingredient is heat-stable, it may be prepared in a hard candy base. Syrup is concentrated to the point at which it becomes a pliable mass, the active ingredient is added, and the mixture is kneaded while warm to form a homogeneous mass. The mass is worked gradually into a pipe form having the diameter desired for the candy piece, and the lozenges are cut from the pipe and allowed to cool. This is an entirely mechanical operation with equipment designed for this purpose.

If the active ingredient is heat-labile, it may be made into a lozenge preparation by compression. The granulation is prepared in a manner similar to that used for any compressed tablet. The lozenge is made using heavy compression equipment to give a tablet that is harder than usual, as it is desirable for the troche to dissolve or disintegrate slowly in the mouth. In the formulation of the lozenge the ingredients are chosen that will promote its slow-dissolving characteristics. Compression is

gaining in popularity as a means of making troches and candy pieces because of the increased speeds of compression equipment. In cases in which holes are to be placed in troches or candy pieces, core-rod tooling is used (Fig 45-52). Core-rod tooling includes a rod centered on the lower punch around which the troche is compressed in the die cavity. The upper punch has an opening in its center for the core rod to enter during compression. It is evident that maximum accuracy is needed to provide alignment as the narrow punches are inserted into the die.

CACHETS

Related to capsules, inasmuch as they provide an edible container for the oral administration of solid drugs, cachets formerly were used in pharmacy. They varied in size from $\frac{3}{4}$ to $\frac{1}{2}$ inch in diameter and consisted of two concave pieces of wafer made of flour and water. After one section was filled with the prescribed quantity of the medicinal agent, they were sealed tightly by moistening the margins and pressing them firmly together. When moistened with water, their character was changed entirely; they became soft, elastic, and slippery. Hence, they could be swallowed easily by floating them on water.

PELLETS

The term pellet is sometimes applied to small, sterile cylinders about 3.2 mm in diameter by 8 mm in length, which are formed by compression from medicated masses.⁵⁵ Whenever prolonged and continuous absorption of testosterone, estradiol, or desoxycorticosterone is desired, pellets of these potent hormones may be used by implantation.

MEDICATED CHEWING GUM

Chewing gum has been a widely popular form of confection that has its roots in ancient times. Only recently has its use as a drug delivery system become mainstream. Worldwide, there are commercially available chewing gums for use in smoking cessation, pain relief, and motion sickness. Chewing gum can also offer an advantage for localized delivery of drugs in the mouth, and is now being evaluated for these uses.⁵⁶⁻⁶⁰

Gums can be manufactured by a variety of mixing processes that incorporate several components into a sheet of product,




Figure 45-52. Core-rod tooling for compressing troches or candy pieces with hole in center (courtesy, Vector/Colton).

Table 45-6. Formula of a Medicated Chewing Gum

COMPONENT	CONCENTRATION (%W/W)
Drug	0–40
Gum Base	20–45
Sweeteners	30–60
Softeners	0–10
Flavor(s)	1–5
Color(s)	0–1

whereby the units are stamped or cut from the rolled out sheet. A typical formulation for a chewing gum might be considered in Table 45-6.

Chewing gums can be made by compression and other processes, but the predominant method in use today is mixing, rolling and stamping of the finished units. After the finished units are completed, they can be film or sugar coated for better mouth feel or taste improvement.

RAPIDLY DISSOLVING TABLETS

Recently, a number of fast-dissolving tablets have been produced to rapidly deliver drugs for a variety of applications. One of the first solid dosage forms, Zydis (RP Scherer) used lyophilized technology to prepare the powder to dissolve quickly on the tongue. Since then, numerous technologies have been developed to give quick dissolution of the active in the mouth. Other technologies such as Lyoc (Farmalyoc), WOW-Tab (Yamanouchi), Flash-Dose (Biovail), Orasolv (CIMA) and DuraSolv

(CIMA) have been used in commercialized products. There are some comparable benefits to one technology over the others, but the objective is still the same. These products have had some acceptance, and will have a place in formularies for years to come.


The challenges these dosage forms have had is durability during shipping, and changes to the drug substance that can occur during the lyophilization or manufacturing process. In addition, these products are best suited for drugs where there is a demonstrable benefit from very fast onset of activity of the drug. To date, there have been few clinical studies to show the significance of benefit of these products over standard immediate-release products.

TABLETS MADE BY ELECTROSTATIC DEPOSITION


The most common example of electrostatic deposition takes place every day in the office photocopy machine. The basic principle of electrostatic deposition is well-founded in basic physics: opposite charges attract. Deposition of material occurs when a pattern of charges is established on the substrate where the deposition is desired, and very fine particles with an opposite charge is placed near the substrate. The Sarnoff Research Laboratories developed an electro-static method of depositing and thereby coating solid surfaces with powder in a dry form. This technology was initially developed for phosphorus coating for cathode ray tubes, and was first applied to the manufacture of tablets by Delsys Corporation, now merged with Elan Corporation.^{61–65}

Figure 45-53 illustrates this process. A substrate is chosen as the base for the deposit of particles. The charging is done us-

Charge Image Circuit



Apply Potential



Deposit Powder




Figure 45-53. Electrostatic powder deposition process.

ing a three-layer structure that has a conducting backplane electrode, an insulating layer and a patterned conducting top electrode. Application of a positive voltage to the backplane electrode establishes a positive surface charge in the electrode. Charges that mirror the backplane charges are induced in the conductive top electrodes. In the floating electrodes, negative mirror charges induced by the backplane electrode leave uncompensated positive charges in the top surface of the floating electrode. By controlling the amount and strength of these positive charges, the rate of deposition and porosity of the resulting solid can be controlled.

The electrostatic process has several potential applications. First, the uniformity of ultra low dose drugs could be precisely achieved. Drugs with significant stability or incompatibility problems could be easily addressed without separate operations. Because little or no excipients are used in this process, the cost, storage and movement of materials in the modern manufacturing facility may be reduced significantly. In addition, it may be possible to have a final formulation designed and finalized much earlier in the development process. Currently, there are no commercial tablets using this technology, but one can imagine the considerable issues associated with the scale-up, validation and implementation of this technology.

THREE-DIMENSIONAL PRINTING OF TABLETS

Another technology that has been adapted for the manufacture of tablets is three-dimensional printing, called 3DP by Therics Corporation, the company to first apply this technology to pharmaceuticals. The technology is quite similar to ink-jet printer technology. It was improved by engineers at the Massachusetts Institute of Technology, and later at Therics.

Figures 45-54 and 45-55 illustrate three-dimensional printing.⁶⁶ In Figure 45-54, the basic system is shown. Powder is spread into a tray and binder droplets are precisely sprayed onto a substrate to form virtually any shape or design. A piston holding the unit changes position for each pass of the dispensing module, allowing for a build-up of the tablet. The process is repeated over and over until the desired shape is obtained. Using a tray that can accommodate many hundreds of powder wells, and hundreds of dispensing modules would be required to make this unit suitable for commercial manufacture. To this date, there are no commercial tablets made from this technology. However, its versatility and complete freedom for design of novel solid dosage forms make this technology fascinating. Figure 45-55 illustrates this point showing a design on the computer screen, with a tablet completed next to it. In the cutaway section can be seen many programmed




Figure 45-55. Design versatility of three-dimensional printing.

walls and empty compartments “constructed” within the confines of the tablet.

Three-dimensional printing technology has all of the advantages of electrostatic powder deposition, but has many more practical applications.

WEB-COATED SYSTEMS

In the early 1980s, Roche laboratories developed a system whereby sheets of a substrate were coated with drug and binder solution.⁶² A number of sheets were then laminated, or glued together to form a complex, multi-layered sheet containing drug and various binder/excipient systems. The final laminate sheet was then punched to produce many dosage forms. This system was quite flexible, and was capable of producing various types of controlled-release, and combination products. However, due to its impracticality, it was abandoned by Roche in the mid-1980s. It remains an important development, and is instructive from a historical perspective.




Figure 45-54. Three-dimensional printing process.

HOT-MELT EXTRUSION

Hot-melt extrusion technology has been extensively used as a processing technique in the plastics industry and is currently being investigated in the pharmaceutical arena as a novel tableting method. The process involves the active, suitable polymeric carrier, and other excipients being mixed in the molten state and then extruded through a die. The final product may take the form of a film, pipe, tube, or granule, depending on the shape of the die. A matrix is formed due to the melted polymer acting as a thermal binder. In addition to being anhydrous, this technology offers the advantage of tableting poorly compressible materials and manufacturing sustained-release tablets. The thermal stability of each material must be sufficient to withstand the production process.

REFERENCES

- Rowland M, Tozer TN. *Clinical Pharmacokinetics: Concepts & Applications*. Baltimore: Lippincott Williams & Wilkins, 1995.
- Kottke MK, Rudnic EM. In BankerGS, Rhodes CT, eds. *Modern Pharmaceutics*. New York: Marcel Dekker, 2002.
- Rathbone MJ, et al, eds. *Modified Release Drug Delivery Technology*. New York: Marcel Dekker, 2003.
- Alderborn G, Nystrom C, eds. *Pharmaceutical Powder Compaction Technology*. New York: Marcel Dekker, 1996.
- Parikh DM, ed. *Pharmaceutical Granulation Technology*. New York: Marcel Dekker, 1997.
- Carstensen JT. *Pharmaceutical Principles of Solid Dosage Forms*. Lancaster: Technomic Publishers, 1993.
- McGinity JW. *Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms*. New York: Dekker, 1989.
- Lieberman HA, Lachman L, eds. *Pharmaceutical Dosage Forms: Tablets*, vols I, II, and III. New York: Dekker, 1980, 1981, 1982, 2nd rev 1989.
- Evans AJ, Train D. *A Bibliography of the Tableting of Medicinal Substances*. London: Pharmaceutical Press, 1963.
- Evans AJ. *A Bibliography of the Tableting of Medicinal Substances*. London: Pharmaceutical Press, 1964.
- Lachman L, et al. *The Theory and Practice of Industrial Pharmacy*, 3rd ed. Philadelphia: Lea & Febiger, 1988.
- Banker G, Rhodes CT. *Modern Pharmaceutics*, 4th ed. New York: Dekker, 2002.
- Ansel HC. *Introduction to Pharmaceutical Dosage Forms*, 3rd ed. Philadelphia: Lea & Febiger, 1981.
- Monkhouse DC, Lach JL. *Can J Pharm Sci* 1972; 7:29.
- de Boer, AG. *Drug Absorption Enhancement*, Switzerland: Harwood, 1994.
- Handbook of Pharmaceutical Excipients*, 4th ed. Washington, DC: APhA/Pharm Soc Great Britain, APhA, 2003.
- Rudnic EM, Kanig JL, Rhodes CT. *J Pharm Sci* 1985; 74:647.
- Rudnic EM, et al. *Drug Dev Ind Pharm* 1982; 8:87.
- Kanig JL, Rudnic EM. *Pharm Technol* 1984; 8:50.
- Rudnic EM, et al. *Drug Dev Ind Pharm* 1981; 7:347.
- Capsugel List of Colorants for Oral Drugs*. Basel: Capsugel AG, 1988.
- Foley VL, Belcastro PF. *Pharm Technol* 1987; 9:110.
- Stewart A. *Engineering* 1950; 169:203.
- David ST, Augsburg LL. *J Pharm Sci* 1977; 66:155.
- Jones TM. In Poldermand J, ed. *Formulation and Preparation of Dosage Forms*. North Holland: Elsevier, 1977, p 29.
- Rees JE, Rue PJ. *J Pharm Pharmacol* 1987; 30:601.
- Summers MP, Enever RP, Carless JE. *J Pharm Sci* 1977; 66:1172.
- Hersey JA, Rees JE. In *Particle Size Analysis*. Groves MJ, Wyatt-Sargent JL, eds. London: Soc Anal Chem, 1970.
- Jones TM. *Acta Pharm Tech* 1978.
- Chowhan ZT. *Pharm Technol* 1988; 12:46.
- Mehta AM. *Pharm Technol* 1988; 12:46.
- Mendes RW, Roy SB. *Pharm Technol* 1978; 2:35.
- Wurster DE. *J APhA Sci Ed* 1960; 49:82.
- Mendes RW, Roy SB. *Pharm Technol* 1978; 2(9):61.
- Malinowski HJ, Smith WE. *J Pharm Sci* 1974; 63:285.
- Woodruff CW, Nuessle NO. *J Pharm Sci* 1972; 61:787.
- O'Connor RE, Holine J, Schwartz JB. *Am J Pharm* 1984; 156:80.
- O'Connor RE, Schwartz JB. *Drug Dev Ind Pharm* 1985; 11:1837.
- Newton JM. *Mfg Chem Aerosol News* 1966; 37(Apr):33.
- U.S. Pat 3,883,647, May 13, 1975.
- Tableting Specification Manual*. Washington DC: APhA, 1981.
- Knoechel EL et al. *J Pharm Sci* 1967; 56:116.
- Wray PE. *Drug Cosmet Ind* 1969; 105(3):53.
- Hiestand EN, Smith DP. *Powder Tech* 1984; 38:145.
- Hiestand EN, et al. *J Pharm Sci* 1977; 66:510.
- Luenberger H. *Int J Pharm* 1982; 12:41.
- Walter JT, Augsburg LL. *Pharm Technol* 1986; 10:26.
- Schwartz JB. *Pharm Technol* 1981; 5(9):102.
- Marshall K. *Pharm Technol* 1983; 7(3):68.
- Jones BE. *Mfg Chem Aerosol News* 1969; 40(Feb):25.
- Delaney R. *Pharm Exec* 1982; 2(3):34.
- Tannenbaum PJ et al. *Clin Pharmacol Ther* 1968; 9:598.
- Ebert WR. *Pharm Technol* 1977; 1(10):44.
- Madan PL. *Pharm Technol* 1978; 2(9):68.
- Cox PH, Spanjers F. *Pharm Weekbl* 1970; 105:681.
- Rassing MR, Jacobsen J. In Rathbone MJ, et al, eds. *Modified Release Drug Delivery Technology*. New York: Marcel Dekker, 2003, p 419.
- U.S. Patent 5,338,809, 1993.
- Christrup LL. *Arch Pharm Chem* 1986; 14:30.
- U.S. Patent 4,740,376, 1987.
- European Patent 486,563, 1990.
- Chrai SS et al. *Pharm Technol* 1998; 12(4).
- U.S. Patent 5,714,007, 1998.
- U.S. Patent 5,753,302, 1998.
- U.S. Patent 5,788,814, 1998.
- U.S. Patent 5,642,727, 1998.
- U.S. Patent 4,197,289, 1980.